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Universal access to antiretroviral therapy (ART) during pregnancy and breastfeeding has 
implications for retention in HIV care and adherence to ART. Retention and adherence may 
be especially challenging during antenatal and postnatal periods, where women living with 
HIV have competing responsibilities between infant care, self-care and personal 
responsibilities. Lifelong ART also highlights the role interconception care (ICC) and 
preconception care (PCC) interventions can play in improving maternal outcomes. While the 
latter exist for other health topics, ICC and PCC interventions targeting women living with HIV 
has the potential to maintain retention in care and  adherence to ART  during,  after, and in 
between pregnancies.  This systematic review evaluates interventions that aim to improve 
retention and adherence in pregnant and postpartum women. 
Methods The Cochrane Library; MEDLINE via PubMed; Web of Science; and EBSCOHOST 
(Africa Wide, Academic Search Premier, CINAHL, PsychArticles, Health Source Nursing 
Academic, PsychInfo) and conference databases were searched for articles in English 
published between 1990 to 2020. All study designs, intervention types and geographic 
locations were included. Data were extracted using a standardized tool, and effect sizes 
recalculated for all studies. Risk of bias was conducted using tools suited to specific study 
designs, and the PRECIS-2 tool assessed intervention applicability in real-world settings. The 
protocol was registered with PROSPERO (ID: CRD42020185196). 
Results Thirty-one studies were identified, of which 31 and 16 provided retention and 
adherence data, respectively. No interconception or preconception care interventions were 
found.  Interventions were predominantly from Sub-Saharan Africa, except one from the USA. 
Intervention types varied and included integration of services, peer support, mhealth and 
multicomponent interventions. The definitions of retention and adherence used for outcome 
assessment varied widely across studies, but almost all were scored as pragmatic in real-world 
settings. Due to high heterogeneity, a narrative approach was used based on study reported 
data and the effect sizes. 
Conclusion Overall, heterogeneity of identified studies make definitive recommendations for 
interventions scale up difficult. Future interventions will benefit from consistent study 
designs, outcome definitions, outcome measurements, validated tools, and longer retention 
time points will strengthen the evidence base. Ongoing studies being conducted show 
promise in addressing some of these points. 
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Women of child bearing age account for the majority of all HIV-infected people globally (1). For HIV-
infected pregnant and postpartum breastfeeding women, antiretroviral therapy (ART) use is critical to 
ensure maternal health and that of the newborn infant.  Previously, pregnant women were either 
temporarily initiated on ART antepartum or at a CD4 count below 350 cells/µl. Under Option B+ and 
more recently universal ART for all people living with HIV, the World Health Organization (WHO) 
recommends pregnant women presenting for antenatal care (ANC) found to be HIV-infected, be 
initiated on lifelong ART regardless of CD4 count and WHO clinical stage (2). However, benefits of 
expanded ART access as well as virological and clinical success, depend on sustained medication 
adherence and retention in care of pregnant and postpartum women (3, 4). Concerns are mounting 
around the low levels of adherence and retention in care observed for these populations (5-7). ART 
non-adherence and non-retention can lead to poor outcomes such as drug resistance, disease 
progression to AIDS, morbidity and mortality in mothers (8-10). The risk of HIV transmission from 
mother to  newborn during delivery, and postpartum through breastfeeding also increases if women 
are lost to follow-up or non-adherent to ART (2, 8).  
 
Data from a recent systematic review (11) showed that pregnant and postpartum women in Africa 
have retention rates of 79.4% and 74.5%, 6 and 12 months respectively, post-ART initiation. These 
estimates are lower than that of the general population of adults living with HIV, in part due to the 
perceived and actual demands of Option B+ (11, 12).  In general women also have lower ART 
adherence than men (13) which has been shown to be suboptimal in pregnancy with further decline 
during the postpartum period (8, 14, 15). Multiple and wide ranging challenges impact women’s HIV 
medication adherence and retention during pregnancy and postpartum (4, 5, 8, 12, 16). In pregnancy 
pill fatigue, treatment side effects, pregnancy associated nausea (5, 17), work commitments, lack of 
male partner involvement (18-20) , poor maternal health due to other illnesses, stigma (17-20) and 
lack of money to visit health facilities have accounted for poor adherence and retention in care (5, 17). 
However, concern for the unborn infant is a strong facilitator for maternal ART adherence, even in the 
face of these obstacles (7).  
 
Postpartum, mothers must contend with the move from concurrent maternal and in utero infant care 
to separate care post-delivery (3). This post-delivery transfer of HIV care is a significant de-motivator 
to postpartum ART adherence (4) and together with work conflicts, financial problems, clinic issues, 
stigma and travel to distant rural homes (3, 11) results in poor adherence and postpartum retention 
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in care. Another significant concern is that healthy delivery of HIV-negative infants leads to further 
lack of motivation for mothers remaining in care (4, 7). The latter is an important reason for lower 
adherence and retention postnatally compared to pregnancy. 
 
Thus antenatal and postnatal interventions focussed on addressing these adherence challenges 
among others are crucial, and assessing which interventions are most successful in promoting 
retention in care for mothers necessary (20). Studies have highlighted the importance of targeted 
interventions and adaptation of programmes to improve adherence and retention in pregnant and 
postpartum women (3, 11). 
 
In addition to antenatal and postnatal interventions, preconception and interconception care (PCC 
and ICC respectively) directed at women living with HIV (WLHIV) have the potential to influence ART 
adherence and retention before, during and after pregnancy. Defined as a set of interventions 
targeted at women and/or couples of childbearing age, regardless of pregnancy status or desire, pre-
pregnancy or between pregnancies, to improve health outcomes for women, newborns and children 
(21), PCC and ICC for HIV-infected individuals are more focused.  This takes the form of promotion of 
safer conception between serodiscordant couples, planned pregnancies, and preventions of HIV 
vertical transmission between the mother and infant (22). 
 
1.2 Rational for the review 
Existing systematic reviews on HIV medication adherence and retention in these populations have had 
limited inclusion criteria considering: restricted geographical locations (5, 11, 20); fewer study designs 
(23); the postpartum period only (16) or lack differentiation between pregnancy and postpartum (11); 
and outcome measures and definitions of adherence which exclude viral load (16, 20). Moreover, the 
search end date of these reviews are outdated being more than 2 years old (5, 16, 20, 23) and none 
focus on PCC or ICC. The current review aims to analyse the most recently available studies, which will 
include conference abstracts to ensure up to date data. Study design selections will be expanded 
beyond randomised control trials and cohort studies; no geographical limitations will be applied; viral 
load as an outcome will be incorporated; and adherence and retention definitions will be increased to 
include multiple types of measures. By broadening the scope of the inclusion criteria, gaps from 
previous studies will be addressed and the resultant analyses - including subgroup analyses - will be 
more comprehensive, allowing both broader and more nuanced conclusions to be made relating 
specifically to interventions targeted at improving antepartum and postpartum HIV medication 




Currently there is no published systematic review or meta-analysis that incorporates all these 
elements, with the requisite potential for the a priori subgroup analyses. Findings across these 
expanded criteria have the potential to assist public health officials and policy makers in evidence-
based decision making in research, healthcare and policy development around effective antenatal and 
postnatal care interventions to improve HIV adherence and retention in maternal populations. It can 
also shed light on whether antenatal or postnatal care interventions offers the greatest potential for 
reaching women to improve adherence and retention. This could provide data on where to direct 
resources to achieve the greatest benefit. 
 
1.3 Research question and Objectives 
Main review question: In HIV-infected women on ART, which antenatal and/or postnatal care 
interventions, preconception or interconception care strategies improve medication adherence and 
retention in care during pregnancy and/or postpartum? 
 
The primary objectives for the review are to assess and synthesise global evidence regarding 
interventions before, during and after pregnancy focused on improving ART adherence and/or 
retention of HIV-infected pregnant and postpartum women during the antenatal and postnatal care 
periods. This would include women initiating as well as conceiving on ART, to further determine: 1) 
the types of antenatal and postnatal care interventions, for pregnant and postpartum women 
respectively, 2) if antenatal interventions improve postpartum adherence and retention outcomes, 3) 
if preconception and interconception care improves ART adherence and retention during the 
antenatal and postnatal periods and 3) what duration and types of interventions are most effective in 
improving ART adherence and retention. 
 
2 METHODOLOGY 
The review will be conducted according to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines (24). 
 
2.1  Inclusion and Exclusion Study Criteria  
2.1.1 Inclusion Criteria 
• All study designs will be considered, including randomised controlled trials, quasi-randomised 
trails, pre/post studies, retrospective and prospective cohorts, and case control studies using 
antenatal or postnatal care interventions to improve ART adherence and/or retention in care 
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• Target population will include HIV-infected women, aged 18 and older, on ART during and 
after pregnancy. This will include women already on ART or those initiating at an ANC visit. Postpartum 
is defined as beginning at 6 weeks with no end period and includes breastfeeding women 
• All types (e.g. peer mentors, mobile health interventions, etc.) and durations (days, months, 
years) of antenatal and postnatal care interventions will be considered, including those targeting 
mothers only, infants only and mother-baby dyads 
• Studies published between 1990 to August 2019 will be considered 
• All geographical regions will be included 
• Studies published in English will be included 
 
2.1.2 Exclusion Criteria 
• Mathematical modelling studies, guidelines, study protocols, reviews and case series will not 
be considered 
• HIV-infected adolescents aged 17 and younger 
• Much of the literature refers to Option B+ as an intervention. Studies that consider Option B+ 
as an intervention will be excluded since this review is not focused on ART eligibility, but on what 
interventions exist for eligible women on ART to improve their adherence and retention in care during 
and after pregnancy. PCC and ICC targeted at WLHIV, will also be considered as it relates to ART 
adherence during pregnancy and postpartum 
• Studies with participants from high-risk or key populations i.e. prisoners, sex workers, etc. 
• Studies published before 1990 
• Studies published in languages other than English 
 
2.2 Outcome 
The review outcome will explore improvement in ART adherence and retention in care post-
intervention. Adherence measures will be categorised as follows: subjective measures (e.g. self-report 
by patients), objective measures (e.g. pill count, pharmacy refill, and electronic device monitoring), 
and biological correlates of adherence (e.g. viral load, plasma drug levels (25). Other measures 
identified from included studies will be categorised into one of these groups. Adherence will be 
defined as per the study author definition, and may be expressed as percentage of medication taken 
correctly for a defined study period (e.g. 100% medication taken for 6 months) or viral suppression. 
 
If multiple adherence measures are presented in a paper, one of which is a combined measure (i.e. 
pooling of 2 or more adherence measures), the single adherence measure outcome/s will only be 
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reported and analysed (i.e. the combined measure will be excluded). However, in the event a study 
only reports combined outcomes, the paper will be retained and reported as a combined measure to 
prevent loss of data by study exclusion.  
 
Retention in care post-intervention will be categorised from the date of initiation of ART according to 
the relevant study defined criteria of a visit e.g. attending clinic appointments. The type of encounter 
considered as a visit will also be study defined e.g. doctor appointment, medication pick-up, follow-
up contact etc. Retention measures considered will be numbers/proportion: retained in care and lost-
to-follow-up (as reported in the study, including those who died, and stopped treatment). Women will 
be considered retained if reported as transferring care or not following other aspects of care while 
still attending visits (11). Other measures, and possibly duration of time (e.g. between visits or since 
the last visit), may later be identified from included studies. If the data allows, the suggested definition 
of retention of care from a recent systematic review (11), i.e. having attended a clinic appointment 
within the last 90 days, will be calculated from study data. 
 
2.3 Search strategy for identification of studies 
A comprehensive literature search will be performed to enable capturing of as many relevant articles 
as possible. The following online electronic databases will be searched from 1990 to 2019: the 
Cochrane Library; MEDLINE via PubMed; Web of Science; Academic Search Premier, Africa Wide, 
CINAHL, Health Source Nursing Academic, PsychARTICLES via the Ebscohost platform; and Global 
Index Medicus. Conference abstracts to be searched until 2019 include AIDS, the International AIDS 
Society (IAS), and the Conference on Retroviruses and Opportunistic Infections (CROI), which will be 
compared to the search results to ensure that all relevant articles are considered in this review. 
Reference lists of relevant studies will be searched for further articles. No geographical limitations will 
be applied. Medical subject headings (MeSH) and text words related to HIV, ART, pregnancy, 
postpartum, breastfeeding, interventions, treatment adherence and retention, will be used (Table 1).  
Guidance from the medical librarian at the Health Sciences Library at the University of Cape Town will 
be sought before the final search processes are performed. 
 
Table 1: Keywords and MeSH Terms to be used in database searches 
Search Query 
#1 
Search ((HIV [MeSH Terms]) OR HIV Infections [MeSH Terms]) OR ((HIV OR HIV-1 OR HIV-2 
OR HIV1 OR HIV2 OR Human Immunodeficiency Virus OR Human Immunedeficiency Virus 
OR Human Immune-Deficiency Virus OR Human Immuno-Deficiency Virus OR Acquired 




Immuno-Deficiency Syndrome OR Acquired Immune-Deficiency Syndrome OR Nevirapine 
OR Zidovudine)) 
#2 
Search ((Antiviral Agents [MeSH Terms]) OR Antiretroviral Therapy, Highly Active [MeSH 
Terms]) OR ((anti-AIDS OR anti-HIV OR anti HIV OR antiretroviral OR anti-retroviral OR anti 
retroviral OR HAART)) 
#3 
Search ((((Pregnancy [MeSH Terms]) OR Pregnant Women[MeSH Terms]) OR Postnatal 
Care[MeSH Terms]) OR Postpartum Period[MeSH Terms] OR Preconception Care[MeSH 
Terms]  ) OR ((pregnant OR antenatal OR interconception OR postnatal OR perinatal OR 
postpartum OR preconception OR prenatal OR mother-to-child OR MTCT OR mother-to-
infant OR maternal-infant transmission OR PMTCT)) 
#4 
Search ((((Treatment Adherence and Compliance [MeSH Terms]))) OR Lost to Follow-Up 
[MeSH Terms]) OR ((adherence OR engagement OR care acceptor OR compliance OR patient 
acceptance OR retention OR loss to follow up OR lost to follow-up OR lost to follow up OR 
linkage to care OR pharmacy refill OR self-report OR electronic device monitoring OR plasma 
drug levels)) 
#5 #1 AND #2 AND #3 AND #4 
 
3 DATA COLLECTION AND ANALYSES 
3.1 Study selection 
All titles and abstracts identified by database searches will be entered into a reference manager 
(Endnote) and duplicates removed manually.  These will be screened in duplicate by two reviewers 
and articles for full text review identified. The full text review of relevant articles will also be performed 
in duplicate to determine the final selection of articles for inclusion in the review.  
 
3.2 Data extraction  
Data extraction will be performed according to a standardised extraction form in duplicate by two 
separate reviewers. Discrepancies will be resolved by discussion and consensus with resolution by a 
third senior reviewer where necessary.  A pilot extraction with a draft extraction form will be 
performed on approximately 10 articles to determine if all relevant information from interventions 
are being captured. Currently the data to be extracted from each study includes: first author, year, 
country, rural/urban setting, study design, study duration, populations (mother/infant/both), 
pregnancy/postpartum, infant age, adherence measure, adherence definition, control group, 
antenatal/postnatal intervention, type of intervention, duration of intervention, who the intervention 




3.3 Assessing risk of bias  
Assessment of study quality of included studies will be performed independently in duplicate by two 
separate reviewers. Discrepancies will be resolved by discussion and consensus with resolution by a 
third senior reviewer where necessary. Due to varied study designs anticipated, two different tools 
have been identified to assess risk of bias. For randomised trials the tool recommended by the 
Cochrane Collaboration (26) will be used, which includes domains related to sequence generation, 
allocation concealment, masking of participants and outcome assessors, incomplete outcome data, 
and selective outcome reporting covering a range of potential biases. For non-randomised studies the 
ROBINS-I (Risk Of Bias In Non-randomised Studies of Interventions) tool will be used (27) Domains for 
this tool include bias due to confounding and participant selection (pre-intervention), bias in 
classifications of interventions (at intervention), and bias due to deviation from intended 
interventions, missing data, outcome measurements and selection of reported results (post-
intervention). 
 
3.4 Dealing with missing data 
It is expected that some published articles may be inaccessible. The University of Cape Town has high 
access to published journal articles but where embargo periods or journal subscriptions prevent 
accessing of relevant articles, study authors will be contacted. This will also be done where full data is 
unclear or missing. A request for the article or data will be sent to the corresponding author, and in 
the event of a non-response a follow up email will be sent. If the requested information is not sent or 
the author does not respond after two attempts, the article in question will be excluded from the 
study. 
 
3.5 Measure of intervention effect 
Data will be analysed using Review Manager 5.3 (Cochrane Collaboration, 2008). The likely 
nature of the adherence outcome will be dichotomous (adherent or non-adherent). It is anticipated 
that effectiveness of interventions from each study will be expressed as an odds ratio (OR) or risk ratio 
(RR) with 95% confidence intervals.  
 
3.6 Assessment of heterogeneity 
Heterogeneity will be assessed with Cochran’s Q statistic and the I² statistic (28) I2 values greater than 
75% indicate substantial heterogeneity while a low degree of heterogeneity (50% or lower) will 
indicate a meta-analysis is possible.  In the event of homogenous studies, a fixed effects model will be 
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used to determine pooled effects. Alternatively, a random effects model will be used if interventions 
are heterogeneous.   
 
3.7 Subgroup analysis  
A priori subgroups have been identified for subgroup analysis, and will be conducted if possible from 
data extracted (it should be noted that in some cases data may be insufficient to allow these analyses). 
These will include stratifying and analysing studies by: study design; antenatal or postnatal 
intervention, ICC or PCC; interventions geared towards mothers only, infants only or the mother-infant 
dyad; intervention type; duration of intervention; type of adherence measure; and duration of 
postpartum period by breastfeeding or non-breastfeeding mothers. While not a subgroup analysis, 
the ART eligibility policy at the time of the study will also be considered in the assessment of the results 
e.g. when women began ART at CD4 count of <350 when compared to Option B+. 
 
3.8 Presenting and reporting of results 
A descriptive narrative approach will be adopted for results reporting if there is substantial 
heterogeneity in included studies. Results will be presented using a combination of tables, figures 
and/or graphs where appropriate. Forest plots will be used to assess heterogeneity of included 
studies, and where the latter is high summary tables will be generated to summarise data. Chi-squared 
tests will be conducted to assess between study homogeneity. Funnel plots assessing publication bias 
will also be reported. Excluded studies will be tabulated, together with justification for exclusion. 
 
The second, validated Pragmatic–Explanatory Continuum Indicator Summary (PRECIS-2) (29) tool will 
be used to evaluate whether identified interventions are pragmatic or exploratory. This will aid 
assessment of intervention performance in real world settings. The tool consisting of 9 domains 
(eligibility criteria, recruitment, setting, organisation, flexibility regarding delivery), flexibility 
regarding adherence, follow-up, primary outcome, and primary analysis) will be reported either 
diagrammatically or tabulated depending on our results.  
 
4 ETHICS  
Given that this is a systematic review of publicly available, published data, there will be no direct 
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Background Universal access to antiretroviral therapy during pregnancy and breastfeeding 
has implications for retention in HIV care and adherence to antiretroviral therapy (ART). 
Retention and adherence may be especially challenging during antenatal and postnatal care, 
where women living with HIV have competing responsibilities between infant care, self-care 
and personal responsibilities. Lifelong ART also highlights the role interconception and 
preconception care interventions can play in improving maternal outcomes. This systematic 
review evaluates interventions that aim to improve retention and adherence in pregnant and 
postpartum women. 
Methods We searched Pubmed, Scopus, Web of Science, Cochrane Library, EBSCOhost and 
conference databases for articles in English published between 1990 to 2020. All study 
designs, intervention types and geographic locations were included. Data was extracted using 
a standard tool, and effect sizes recalculated for all studies. Risk of bias was conducted using 
tools suited to specific study designs, and the PRECIS-2 tool assessed intervention applicability 
in real-world settings. 
Results Thirty-one studies were identified, of which 31 and 16 provided retention and 
adherence data respectively. No interconception or preconception care interventions were 
found.  Interventions were predominantly from Sub-Saharan Africa, except one from the USA. 
Intervention types varied and included integration of services, peer support, mhealth and 
multicomponent interventions. The definitions of retention and adherence used for outcome 
assessment varied widely across studies, but almost all were scored as pragmatic in real-world 
settings. Due to high heterogeneity, a narrative approach was used based on study reported 
data and the effect sizes. 
Conclusion Overall, heterogeneity of identified studies make definitive recommendations for 
interventions scale up difficult. Future intervention evaluation will benefit from consistent 
study designs, outcome definitions, outcome measurements, validated tools, and longer 
retention time points will strengthen the evidence base. Ongoing studies being conducted 
show promise in addressing some of these points. 
Keywords: HIV, antiretroviral therapy, adherence, retention, interconception care, 





In recent years global prevention of mother to child HIV transmission (PMTCT) policies have 
shifted to focus on universal, lifelong antiretroviral therapy (ART) for all pregnant and 
breastfeeding women [1]. While beneficial to ensure reduced vertical HIV transmission to 
infants and improved maternal outcomes, this approach relies on sustained retention in care 
and adherence to ART [2]. Suboptimal retention and adherence leads to poor outcomes 
including ART resistance, virologic rebound, uncontrolled viraemia, disease progression and 
increased risk of vertical transmission to the infant if the mother is breastfeeding  [2-4].  
 
Data from a recent systematic review showed that pregnant and postpartum women in Africa 
have low retention rates of 79.4% and 74.5%, 6 and 12 months respectively, post-ART 
initiation [5]. Another review showed pooled estimates for adequate adherence (≥80%) were 
low antenatally and even more postnatally, at 73.5% and 53% respectively [6]. There are 
several reasons for suboptimal maternal care during pregnancy and postpartum. These 
include: pill fatigue [6]; ART side effects [7, 8]; forgetting to take medication[9, 10] lack of 
partner or family support [6, 7]; perception that care is not needed [9, 11]; time commitments 
[9, 11]; transportation logistics and costs[11]; poor health care workers (HCWs) attitudes [7, 
11, 12]; stigma [13, 14]; lack of HCW confidentiality [15]; clinic distance [7, 8] and patient 
readiness for ART initiation. Other unique barriers exist, such as pregnancy associated nausea 
and heartburn which can be worsened by ART [6]. Women diagnosed positive and initiating 
ART during pregnancy can also be overwhelmed by the trifecta of reconciling with their 
diagnosis, adjusting to being pregnant, and the prospect of facing an ART regimen daily, for 
life (9). Postpartum, women have to balance recovering from childbirth, breastfeeding, 
emotional stressors associated with caring for a new born and potentially, postpartum 
depression [2, 6, 7, 16]. During the antenatal period, maternal motivation for remaining in 
care is tied to protecting the unborn infants health, but post-delivery mothers consider their 
own treatment less important [17]. Additionally, after birth women are faced with a move 
from concurrent maternal and in utero infant care to separate care post-delivery [11, 18], a 
significant demotivator to retention and adherence [2], while facing challenges of caring for 
a new infant [7]. Some mothers who have not disclosed their HIV status to family, feel they 
no longer have an acceptable reason for clinic attendance post-delivery [18]. These scenarios 
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account for higher retention and adherence levels seen in antenatal care (ANC) compared to 
postnatal care (PNC), highlighting the critical need for implementation of effective, evidence 
based interventions to enhance retention and adherence during these periods.  
 
Previous systematic reviews of interventions to improve retention found mixed results [19] 
and a weak evidence base of interventions targeted at improving retention in postpartum 
women although phone based interventions showed efficacy at 3 months postnatally [20].  
However, this is still very early in the postpartum period. Poor retention across various ART 
regimens point to the need for effective interventions rather than simpler regimens to 
address HIV care retention [21]. 
   
In addition to ANC and PNC interventions, preconception and interconception care (PCC and 
ICC, respectively) can address maternal health over broader periods outside of pregnancy and 
postpartum. PCC and ICC are defined as sets of interventions directed at women and/or 
couples of childbearing age, regardless of pregnancy status or desire, pre-pregnancy or 
between pregnancies, to improve health outcomes for women, newborns and children (22). 
While PCC and ICC interventions have been  explored for maternal substance use, nutrition,  
diabetes and obesity to improve parental behaviours and outcomes  [22], those in the  field 
of HIV are lacking.  PCC and ICC for HIV-infected individuals are more focused taking the form 
of promotion of safer conception between serodiscordant couples, planned pregnancies, and 
prevention of HIV vertical transmission between the mother and infant [23]. PCC and ICC 
directed at women living with HIV (WLHIV) thus has the potential to influence retention and 
ART adherence before, during and after pregnancy. 
 
The challenges, consequences and implications described above underscore the critical need 
for effective interventions to retain pregnant and postpartum women in care and keep them 
adherent to ART. This systematic review aims to: 1) identify all interventions that address 
adherence to ART and retention in care for pregnant and postpartum women as well as those 
in ICC or PCC stages; 2) determine which interventions successfully improve these outcomes; 





2.1 Search strategy  
The following online electronic databases were searched from January 1, 1990 to January 7, 
2020: the Cochrane Library; MEDLINE via PubMed; Web of Science; and EBSCOHOST (Africa 
Wide, Academic Search Premier, CINAHL, PsychArticles, Health Source Nursing Academic, 
PsychInfo). Conference abstracts searched non-exhaustively until December 2019 included 
AIDS, the International AIDS Society, and the Conference on Retroviruses and Opportunistic 
Infections. Secondary references were obtained from searching reference lists of relevant 
studies and reviews. No geographical or language restrictions were applied. Medical subject 
headings (MeSH) and text words related to HIV, ART, pregnancy, postpartum, breastfeeding, 
interventions, treatment adherence and retention were used (S1 Table).  The protocol was 
registered with PROSPERO (ID: CRD42020185196). 
 
2.2 Inclusion and exclusion criteria 
Studies were included if they: (a) were in English, (b) were published after 1990, (c) included 
pregnant or postpartum women living with HIV as the target population (either on or newly 
initiated on ART), (d) evaluated an intervention with a primary or secondary outcome of 
retention in care or adherence to ART; (e) had study designs with or without a control or 
comparison group, and (f) were from any geographic region. Studies with HIV uninfected 
pregnant or postpartum women, that referred to therapeutic ART regimens as an 
intervention, or with high risk populations, were excluded.  Studies focusing on infants as the 
study population were considered only if they reported maternal outcomes separately or 
reported data for mother-infant pairs (MIPs). Studies reporting only infant outcomes were 
excluded. Dissertations, reviews, case reports, studies reporting no quantitative data, and 
qualitative studies were excluded. Relevant abstracts and ongoing studies without results 
were excluded but compiled into a non-exhaustive list and reported separately. 
 
Study populations were categorised as: pregnant, if women were recruited and evaluated in 
pregnancy only; postpartum, if the intervention recruited and followed up women or MIPs 
during the postpartum period; and pregnant/postpartum if they were recruited during 




2.3 Data extraction 
One reviewer screened search results and extracted data independently, with issues resolved 
through discussion with a second reviewer. Using a standardised extraction template, data 
was extracted regarding: author, publication year, country, study design, period of data 
collection, length of follow up, study population, intervention type and description, control 
description, sample size, outcome measure(s) and definitions, and study results.  
 
2.4 Risk of Bias 
Risk of bias (ROB) was assessed using 3 tools from the COCHRANE collaboration. For 
randomised controlled trials (RCTs) the ROB-2 (updated in 2019) for individually randomised 
trials [24], and a similar version of this tool with additional questions specific to cluster-
randomised controlled trials (cRCTs)[25] was used to assess respective study designs. Studies 
were categorised as being either critical, high, some concerns or low risk of bias. Non-
randomised trials were assessed using ROBINS-I (Risk of Bias in Non-randomised Studies of 
Interventions) [26].  ROB was assessed for each overall outcome for studies reporting more 
than one outcome.  All ROB figures were generated using the robvis online tool [27]. One 
reviewer assessed ROB with uncertainties resolved through discussion with the second 
reviewer. 
 
2.5 Data analysis 
Apart from extractions of author reported risk ratios (RRs) or odds ratios (ORs), effects sizes 
were recalculated as ORs with 95% confidence intervals (CIs) for each outcome. Analysis was 
conducted on subgroups by outcome, study population, intervention type and outcomes 
measures. The large degree of heterogeneity generated from preliminary analysis of results 
meant a descriptive narrative approach would be adopted with measures of associations 
reported per subgroup [28]. Review manager 5.3 was used to generate analysis forest plots 
for subgroups. 
 
The validated Pragmatic–Explanatory Continuum Indicator Summary (PRECIS-2) tool was used 
to evaluate if interventions were very pragmatic or rather pragmatic (score of 5 or 4), equally 
pragmatic/exploratory (score of 3), or very or rather explanatory (score or 1 or 2) to indicate 
intervention performance in real world settings[29]. Each included study was assessed across 
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the 9 domains - eligibility criteria, recruitment, setting, organisation, flexibility regarding 
delivery, flexibility regarding adherence, follow-up, primary outcome, and primary analysis. 
Average PRECIS-2 scores and standard deviations were calculated for each study and domain 
by intervention and outcome. This assessment was completed by one reviewer with issues 
resolved through discussion with a second reviewer. 
 
3 RESULTS 
3.1 Search Results 
Database results retrieved 6082 records with an additional 17 identified through reference 
lists of included articles and relevant reviews (Fig 1). After removing duplicates, screening 
abstracts, and full-text review of 126 articles, 33 [30-62] studies met the full inclusion criteria. 
In total 93 studies were excluded (S2 Table). No studies explored interventions implemented 
in ICC or PCC periods.  
 




3.2 Characteristics of included studies 
Sixteen and 31 articles provided data on adherence and retention, respectively. Many studies 
assessed both outcomes in both pregnant and postpartum women (Fig 2a). Intervention types 
were categorised as far as possible into broad groups: mHealth, including text messages and 
phone calls; model of care, which was composed of service delivery models and integrated 
care models; peer support which was composed of mentor mothers, expert mothers and any 
type of peer related support; financial incentives; quality improvement (QI); task shifting; 
cognitive behavioural risk reduction and multicomponent interventions. The latter was 
labelled as such since most studies in this group combined multiple interventions from the 
former groups. Characteristics of included studies by intervention type, location and study 
design are given in Figs 2a., 2b. and 2c. respectively. 
 
2a.   
 





















































































2c.    
 
Figure 2: Study characteristics of included studies by outcome are described by: 2a) 
intervention type 2b) location and 2c) study design. Both refer to studies investigating both 
adherence and retention outcomes. 
 
3.3 Retention 
Descriptions of interventions focussing on retention are given in Table 1.   Individual study 
sample sizes ranged from 71 to 3150.Pooled sample sizes from all studies included 671 
pregnant women (n=3) and 6239 postpartum women (n=5).  The remaining studies (n=23) 
that recruited women during pregnancy and followed them through to postpartum has 
pooled sample sizes of 15611 women.  
 
Maternal retention was measured at varied, multiple time points across studies from short 
term (ranging from the second ANC visit and delivery to 14 weeks postpartum) to longer term 












































POPULATION INTERVENTION DESCRIPTION CONTROL DESCRIPTION 
ADHERENCE CLUBS 








Community-based adherence clubs separate from health facilities aided by lay 
counsellors, symptom review and HIV/health-related group educational talks 
at each 2 to 4 monthly visit (average 5 per year per club).  Prepacked ART 
dispensed, patients permitted proxies to collect medication. Within club 
system clinical review annually with nurse evaluation and VL testing 
Referral to local PHC 
APPOINTMENT TRACKING 
Ross-Degnan, 
2017 Tanzania cRCT 
April 2015 to 
April 2016 6 months RCH clinics postpartum 
Paper based appointment tracking and community outreach consisting of 
training, supportive supervision, and early community-based follow-up to 
encourage return to care using standardized paper-based appointment 
register, another register to track patients missing appointments; and 
monitoring monthly proportion of patients attending appointments on time. 
MOHSW’s previous 





2017 USA retrospective 2005 to 2013 
≤90 days post-




Perinatal Medical Case Management Program: case workers worked with 
WLWH during pregnancy until 1 year postpartum providing psychosocial 
support, addressing structural, psychosocial and other barriers to medical care, 
and identifying unmet needs.  
Women with HIV not in 
PCM 
COMMUNITY HEALTH WORKERS 
Nance, 2017 Tanzania cRCT May 2015 to March 2016 






CHW-led ART adherence counselling; defaulter tracing, distribution of Action 
Birth Cards a birth planning tool as an ANC visit reminder. CHW helped women 
plan for delivery, and encouraged HIV+ women to receive care 
No CHW led intervention 




delivery during ANC pregnant, postpartum 
CHW based defaulter tracing by mobile phone, or if no number/unsuccessful 
call, home visit. Tracing letters left if no personal contact could be made. 
Returning defaulters received minimum one counselling session. 
None 
COUPLES HIV COUNSELLING AND TESTING 
Wesevich, 




1 month post ART 
initiation first ANC visit pregnant 
Paper invitations only versus paper invitations plus phone and physical partner 





2016 DRC RCT 
April 2013 to 
August 2014 6 weeks postpartum 
<32 weeks gestation 
registered for ANC 
pregnant, 
postpartum 
SOC and US$5, plus US$1 increase at every subsequent visit if woman attended 
scheduled visits, provided blood sample for CD4 count on request, accepted 
ART referral, delivered in a health facility, provided blood sample for infant 







April 2013 to 
August 2014 
messages sent until 
infant 6 weeks PCR 
test 
1st or 2nd ANC visit pregnant, postpartum 
Unidirectional, twice weekly MAMA SMSs offered to ANC patients providing 
maternal health information during pregnancy and 1 year after birth. Messages 
timed to gestational/infant age and covered maternal health and HIV-support 
No SMS 
Odeny, 2014 Kenya RCT April 2012 to March 2013 8 weeks postpartum 
attending ANC, 




14 text messages (eight during pregnancy, six postpartum), weekly calls from 
38 weeks’ gestation until delivery. Participants in both arms were allowed to 
call or send SMS to the study nurse at any time. 
SOC contact by phone / in 
person if visit missed. 
Odeny, 2019 Kenya swcRCT February 2015 to 
8 weeks after 
delivery 
attending PMTCT, 




Texting Improves Testing (TextIT), 14 text messages during pregnancy and after 
delivery, option to respond to text messages, call, or send inquiry text 






Sarna, 2019 Kenya RCT 









SOC + Healthy Mother Healthy Baby Project: individualised counseling support 
via phone. Call number varied depending on presentation for ANC services 
(max 42). Sessions consisted of 2 calls in first week of starting PMTCT services, 
then 1 call/week until delivery (max 26 calls), followed by 2 calls during the first 
week after delivery and 1 call/week for next 14 weeks (max of 16 calls) 
Routine HIV counselling 






May to July 
2013 
6  weeks, 12  
months  
postpartum 




Weekly text messages and 1 pre-delivery and 2 post-delivery calls from a case 
manager until 6 weeks postpartum (or 8 weeks if participant did not return for 
6wk clinic visit) to encourage remaining in care and give support.  
No text 
MODEL OF CARE 
Mwapasa, 
2017 Malawi cRCT 






Promoting Retention among Infants and Mothers Effectively (PRIME): 1. MIP 
ARM: integrated MIP clinics with HIV, maternal and child health services at a 
one time and access point, offered 2x per week monthly. 2. MIP + SMS: 
Services provided at one time and access point with use of SMS to notify 
community based volunteers to trace mother/infant defaulter 
SOC provided at multiple 
times and access points 
 (Usual non-integrated care 
and patient tracing) 











Local SOC involves integrated Maternal and Child Health (MCH) and ART 
services during pregnancy, following the local SOC. Intervention continued this 
postpartum where women/infants in the MCH clinic received integrated 
maternal ART and paediatric care until end of breastfeeding or a max 1 year 
Transfer from MCH clinic 
after 1st/2nd postpartum 
visit to general ART services, 
infants to separate routine 
child health services 
Turan, 2015 Kenya cRCT June 2009 to March 2011 
within 6 months of 
enrollment in care ANC 
pregnant, 
postpartum 
Integrated care at ANC and HIV care and treatment in the same clinic until 18 
m post-partum 
SOC (ANC referral for HIV 
care and treatment at same 
facility but different clinic) 
Washington, 
2015 Kenya cRCT 
June 2009 to 
March 2011 
12 months after 
enrolment during pregnancy 
pregnant, 
postpartum 
Combined ANC, PMTCT, and HIV care and treatment in the same clinic. Same 
clinician provided ANC and postpartum services including EID until a definitive 
paediatric HIV diagnosis was obtained or infant 18m old. MIP, if HIV infected, 
then referred to long-term care at facility's HIV clinic. 
routine ANC and PMTCT 
services as per national 
Guidelines.  
Weigel, 2012 Malawi pre/post July 2006 to October 2010 
6 months after ART 
initiation first ANC visit 
pregnant, 
postpartum 
3 year model of care involving paper based tracking system, vehicles for 
transport between ANC and ART facilities, establishment of a new HIV care 
centre near the ANC clinic, priority of PMTCT patients, no need for guardians 
for ART initiatiation, information leaflets for HIV-positive pregnant women, and 
an electronic data system for patient care  
NA 
MULTICOMPONENT INTERVENTIONS 
Aliyu, 2016 Nigeria cRCT April 2013 to March 2014 
6 and 12 weeks 
postpartum 
recruited during 




Task shifting from doctors to nurses/ midwives/CHWs, POC CD4 testing, 
integrated mother and infant care, family/ male partner participation (written 
invitations to male partners to attend PMTCT) and community engagement 
SOC referred women to 
nearby secondary level 
clinic 
Fayorsey, 
2019 Kenya RCT 
September 
2013 to 2015 
6 months 
postpartum initiating ANC 
pregnant, 
postpartum 
Lay counsellors provided individualized PMTCT health education, defaulter 
tracing; retention/adherence support; phone/SMS visit reminders; expedited 
service provision, enhancied communication between women and providers, 
problem-solving retention and adherence barriers, providing psychosocial 
support and counselling 
Routine care per national 
guidelines, phone follow-up 
for missed visits, home visit 
if call unsuccessful 
Gill, 2017 DRC cRCT May to October 2015 2nd ANC visit first ANC visit pregnant 
Elombe Standard Operating Procedure (SOP), outlined referral to mentor 
mothers; topics for first counselling visit; counselling sessions, support group 
attendance and nutrition; text/call reminders for second ANC visit; call on day 
of missed visit; home visit  
SOC Mentor Mother 
included counseling at ANC 
and defaulter tracing  
Guillaine, 
2017 Rwanda retrospective 
July 2012 to 
June 2013 
18 months 
postpartum Not mentioned 
postpartum, 
MIPS 
Combined Clinic model: MIP services delivered at single point of care until 
infant 18 months, mothers enrolled in the community based program, received 




provision of artificial milk formula and equipment, porridge and sugar. Monthly 
alerts from electronic medical record system to clinicians for delayed patient 
visits and clinically significant events 
PEER SUPPORT 
Foster 2017 Zimbabwe cRCT July 2014 to October 2015 12m postpartum 




EPAZ (Eliminating Paediatric AIDS in Zimbabwe). “Expert Mothers” coordinated 
facility-based mother support groups, 2x per month by HCWs until 6 months 
postpartum. HCWs and group coordinators aided structured learning activities 
about 8 PMTCT topics over each 4-month cycle. Women received psychosocial 
support from other women during meetings 





Africa cohort 2006 to 2007 







Mamekhaya: mentoring mothers delivered 8 sessions of a cognitive-
behavioural intervention focused on prevention of HIV transmission, 
adherence to pre- and post-natal baby treatment, uptake of EID 
Control site received SOC 
from midwives and 
counsellors 
Hosseinipour
, 2017 Malawi cRCT Not Specified  6 months 
enrolled at HIV 
diagnosis in ANC/ 
postpartum clinic 
pregnant, 










delivery, 6 weeks 
post-cessation of 
BF, 18m postpartum 
HIV+ attending 
PMTCT during study 
period 
postpartum, 
MIPS SOC + psychosocial support provided by the Mentor Mothers from m2m. 
SOC as per Ugandan 
guidelines, 
Phiri, 2017 Malawi cRCT 
November 
2013 to July 
2016 
2 year post ART 
initiation at 12m 
and 24m 
ANC, maternity, 
PNC and ART clinics 




Facility based peer support: SOC, “mentor mothers” gave one-on-one support 
at visits, led weekly clinic-based support groups, contacted women within 1 
week of a missed appointment (by phone call/text message/home visit). 
Community-based peer support, received SOC and “expert mothers” 
conducted routine home visits, HIV education, clinic visit reminders, led 
monthly community-based support group meetings, contacted women in 
community within 1 week of a missed visit and 1 home visit reminder for 
scheduled visit 
SOC, routine HIV care per 
MOH, defaulter tracing for 
women not attending the 
clinic within 60 days of a 
missed appointment 
Richter, 2014 South Africa cRCT 
July 2008 to 
April 2010 
1.5 months post 
birth 
during pregnancy at 
CHC or PHC 
pregnant, 
postpartum 
Masihambisane offered Peer Mentor support to pregnant WLH in PHC clinic 
programs, consisting of 4 ANC and 4 PNC small group sessions in addition to 
SOC 
SOC, based on national 




2017 Nigeria cohort 





unclear, had to have 
attended at least 1 





Structured Mother Mentor (MoMent), comprised an outcome-specific scope 
of work, close mentor mother supervision, standardized documentation, 
performance evaluations 
SOC routine informal, non-
structured peer support 
POC CD4 TESTING AND CD4 COUNT–SPECIFIC ADHERENCE COUNSELING 
Joseph, 2017 Zimbabwe cRCT January 2014 to June 2015 6 and 12 months  




POC Plus (POC CD4 testing with CD4 count–specific adherence counseling) 
 
 














QI teams composed of facility head/medical officer, study nurses/ CHWs, and 
laboratory technicians discussed areas for improvement, tracked changes in 
performance of implemented ideas, adopted/dropped changes based on 
trends. 
 
Routine Nigerian MOH 
support 
VIDEO 





1 month presenting for ANC pregnant 
VITAL Start (Video-intervention to Inspire Treatment Adherence for Life) 
viewing before committing to lifelong ART. Comprised of information, 
motivation and behavioural components, with a video of 27 minutes and a post 
video counselling content of 8 minutes each. 
SOC made up of HCW 
delivered counselling 
session consisting of all key 
concepts in the video 
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Table 2: Results and effect sizes extracted from included retention studies (n=31) in pregnant and postpartum women by intervention. 
AUTHOR, YEAR POPULATION RETENTION OUTCOME MEASURE TIMEPOINT Intervention n/N (%) Control n/N (%) Effect size (95% CI), p-value ROB 
ADHERENCE CLUBS 
Myer, 2017 Postpartum women Remained in study 77/84 (91.6%) 34/45 (75.5%) Not reported Serious€ 
APPOINTMENT TRACKING 
Ross-Degnan, 2017 postpartum One or more visits in last 3 months 1604/1924 (83.4%) 1065/1226 (86.9%) 13.7% net decrease [-15.4,-12.1], p < 0.05 Some concerns§ 
CASE MANAGERS 
Anderson, 2017 HIV+ postpartum women and HIV exposed infants retained 1 year postpartum 236/448 (52.7%) 137/401 (34.2%), 
OR = 2.06 95%CI 1.56-2.71, p <0.0001 
aOR =1.59 95%CI 1.17- 2.16, p = 0.0029 Serious€ 
COMMUNITY HEALTH WORKERS 
Nance, 2017 HIV+ pregnant and postpartum  
retention between 60 - 120 days 
postpartum 138/304 (45.4%) 
d 164/374 (43.9%) d Not reported High§ 
Vogt, 2015 HIV+ pregnant women  retention at delivery post CHW-DT: 496/579 (85.7%) 
pre CHW-DT: 
850/1008 (84.3%) 
RR 1.02 95% CI 0.97 - 1.06, p =0.470 
aRR 1.01 95% CI 0.96 -1.06, p =0.730 Serious€ 
COUPLES HIV TESTING AND COUNSELLING 
Wesevich, 2017 HIV+ pregnant women retention within 31 days 110/126 (87.3%) 48/74 (64.9%) RR 1.35, 95% CI 1.12 - 1.61 (p=0.001)                                                            aRR 1.33, 95% CI 1.12 - 1.59 (p=0.001) Moderate€ 
QUALITY IMPROVEMENT 
Oyeledun, 2017 
HIV+ pregnant women first 
ANC booking ≤34 weeks, 
ART naïve 
Retention in care at 6 months postpartum 117/264 (44.3%) 102/247 (41.3%) aRR: 1.08 95% CI 0.78 to 1.48, p=0.902 
Some concerns § within 90 days before 6 months postpartum 
visit 196/264 (74.2%) 169/247 (68.4%) Effect not reported, p= 0.288 
FINANCIAL INCENTIVE 
Yotebieng, 2016 newly diagnosed HIV+, at ≤32 weeks gestational age Retention at 6 weeks postpartum 174/216 (80.6%) 158/217 (72.8%) 
RR 1.11 95% CI 1.00 to 1.24, p=0.0548 
aRR 1.13 95% CI 1.02 to 1.26, p=0.0243 Some concerns§ 
MHEALTH 
Coleman, 2017 HIV+ pregnant women at first/2nd ANC visit At least 4 ANC visits 60/73(82.2%) 55/94 (58,5%) RR 1.4 95% CI 1.15–1.72, p = 0.001 Serious€ 
Odeny, 2014 HIV+ pregnant women > 28 weeks gestation 
attended postpartum visit ≤ 8 weeks post-
delivery 8/194 (19.6%) 22/187 (11.8%) RR 1.66 95% CI 1.02 to 2.70, p = 0.04 Some concerns¥ 
Odeny, 2019 HIV+ pregnant women >28 weeks gestation retention during first 8 weeks post-delivery 1,548/1,725 (90%) 571 /747 (76%) 
RR 1.18 95% CI 1.03–1.34, p = 0.01 
aRR 1.12 95% CI 0.97-1.30, p=0.1 Some concerns§ 
Sarna, 2019 
14 HIV treatment clinics, 
HIV+ pregnant women 14 - 
36 weeks gestation 
retained at delivery 197/207 (95.2%) 153/197 (77.7%) Ref, p<0,001 
Some concerns¥ retained at 6 weeks pp 183/195 (93.9%) 137/188 (72.9%) HR 0.21 95% CI 0.10, 0.43, p <0.001 
retained at 14 weeks pp 160/192 (83.3%) 125/188 (66,5) HR 0.76 95% CI 0.49, 1.13, p=0.18 
Schwartz, 2015 Recruited HIV+ pregnant 36 weeks gestation  
ART retention at 12m post-deliverya 39/50 (78%)a 38/50 (76%)a Not reported, p=0.71 
Serious€ Actively engaged in HIV care at 10 weeks or 
transferred to another site 47/50 (94%) 48/50 (96%) Not reported, p = 0.65 
MODEL OF CARE 
Mwapasa, 2017 HIV+ pregnant, HIV-exposed infants 
12m maternal postpartum retention MIP 89/461 (19.3%) 
90/396 (22.7%) 
aRR 0.85 95% CI 0.56 to 1.30, p = 0.46 
high§ 
12m Maternal retention MIP+SMS 115/493 (23.3%) aRR 1.08 95% CI 0.87 to 1.35, p = 0.50 
Myer, 2018 HIV+ postpartum  engagement in HIV care at 12m postpartum 188/233 (81%) 168/238 (71%) Not reported, p = 0.013 low¥ 
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Turan, 2015 HIV+ pregnant  ≥ 2 HIV care visits in first 6 months after testing HIV+ in ANC 190/393 (48%) 123/218 (56%) OR 0.73 95% CI 0.47 to 1.14, not significant 
c Some concerns§ 
Washington, 2015 HIV+ pregnant  Retention 12 months 422/569 (74%) 403/603 (66.8%) Not reported Some concerns§ 
Weigel, 2012 HIV+ pregnant, CD4<250, not on ART at 1stANC visit retention 6 months post-ART initiation 2009: 87/133 (65%) 2006: 9/53 (17%) Not reported, p <0.001 Critical€ 
MULTICOMPONENT INTERVENTIONS 
Aliyu, 2016 
HIV+ pregnant women on 
ART presenting for ANC or 
delivery 
MIP retention 6 weeks postpartum 125/150 pairs (83%) 15/170 pairs (9%) RR = 9.4 95% CI 5.5 to 16.1, p < 0.0001 aRR = 9.1 95% CI 5.2–15.9, p = 0.002 
Some concerns § 
MIP retention 12 weeks postpartum 112/150 pairs (75%) 11/168 pairs (7%) RR = 11.4 95% CI 6.1 - 21.2, p < 0.0001 aRR = 10.3 95% CI 5.4 to 19.7, p < 0.0001 
Fayorsey, 2019 HIV+ pregnant women starting ANC Retained at 6 months postpartum 
a 138/170 (81.2%)a 122/170 (71.8%)a Not reported Low¥ 
Gill, 2017 HIV+ pregnant women attending first ANC visit Attended 2nd ANC visit 66/75 (88%) 63/90 (70%) RR = 2.5 95%CI 1.05–5.98, p < 0.002 High§ 
Guillaine, 2017 HIV+ pregnant mothers and infants Retained at 18 months 
a 184/185 (99.5%) a NA None Serious€ 
PEER SUPPORT 
Foster, 2017 HIV+, ≤ 35 weeks gestation and HIV exposed infants 
 point attendance at 12m PNC follow-up 134/188 (71) 98/160 (61) OR 1.46 95% CI 0.92 - 2.30, p = 0.11 
High§ 
regular attendance over 12m PNC follow-up 146/188 (78) 113/160 (71) OR 1.37 95% CI 0.84 to 2.25, p = 0.21 
Futterman, 2010 HIV+ pregnant women Attended FU 23/40 (57.5%) 11/31 (35.5%) RR 1.62 95% CI 0.94 - 2.79, p = 0.097 Serious€ 
Hosseinipour, 2017 HIV+ pregnant and BF women 6 month retention 
FBPS 323/428 (75%) 
312/447 (70%) 
OR 0.81 95% CI 0.45 - 1.40, none reported 
High§ 
CBPS 315/394 (80%) OR 1.13 95%CI 0.61 - 2.12, none reported 
Igumbor, 2019 HIV+ pregnant, MIP 
retention 6 weeks after birth 1123/1161 (96.7%) 752/1143 (65.8%) aOR 12.23 95% CI 5.51 - 27.14, p < 0.05 
Serious€ retention 6 weeks after cessation of breastfeeding 946/1161 (81.5%) 480/1143 (42.0%) aOR 4.93 95% CI 2.98 - 8.12, p < 0.05 
retention 18m after birth 826/1161 (71.2%) 235/1143 (20.6%) aOR 8.65 95% CI 4.80 -15.59, p < 0.05 
Phiri, 2017 HIV+ pregnant 
Maternal retention 12m a 
FBPS: 287/366 (78.4%)a 
270/361 (74.8%)a 
RD 0.06 (-0.06 to 0.18, Not reported 
High§ 
CBPS 267/355(75.2%)a RD 0.08 (0.04 to 0.20), Not reported 
Maternal retention 24m a 
FBPS: 224/277 (80.9%)a 
174/261 (66.7%)a 
RD 0.13 (20.01 to 0.26), Not reported 
CBPS: 216 /258 (83.7%)a RD 0.16 (0.03 to 0.30), Not reported 
Richter, 2014 HIV+ pregnant recruited during pregnancy 
4 or more ANC clinic visits (4 is standard 
practice) AT 1.5 months post delivery 328/377 (87%) 355/466 (76.2) 2.17 95% CI 0.96 - 4.88, p =0.062 High§ 
Sam-Agudu, 2017 HIV+ pregnant, MIPS maternal retention at 6 months postpartum 161/260 (61.9%) 59/ 237 (24.9%) 
OR 5.2 95% CI 2.6 - 10.5, significant b 
aOR 5.9 95% CI 3.0 -11.6, significant b 
Moderate€ 
POC CD4 TESTING AND CD4 COUNT–SPECIFIC ADHERENCE COUNSELLING 
Joseph, 2017 HIV+ pregnant  Retained at scheduled ART visits attended through first 12m on ART 304/603 (50.7) 295/547 (54.5) 
RR = 0.93 95% CI 0.78 - 1.11,   p= 0.426 
aRR = 0.91 95% CI 0.77 - 1.07, p = 0.244 Some concerns§ 
VIDEO 
Kim, 2019 HIV+ pregnant women not on ART retention ART clinic at 1 month 113/146 (77.4%) 120/160 (75%) Not reported, p = 0.69 High¥ 
RR = risk ratio; aRR = adjusted RR; OR = odds ratio; aOR = adjusted OR; €  = ROB assessed via ROBINS-II; § = ROB assessed via ROB 2 for cluster randomised trials; ¥ = ROB assessed via ROB 2 for individually randomised trials 
a. Calculated by including women transferred out to numbers reported 
b. Authors indicated p-value is significant but do not report the value  
c. Authors indicated p-value is not-significant but do not report the value  
d.  date taken from dataset provided in supplementary material filtered by control/ treatment, then endline, then in care) 
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3.3.1 Pregnant and postpartum women 
Overall, 11/23 studies evaluating interventions to improve retention in pregnant and 
postpartum women showed statistically significant effects. Table 2 demonstrates study 
reported retention data and Fig 3 provides recalculated OR’s based on reported n/N’s for 
studies with controls. 
 
Only 2/6 peer support interventions showed statistically significant impacts on retention: 
structured mother mentor compared to routine unstructured sessions improved retention at 
6 months [54]; and facility- versus community-based peer support compared to SOC improved 
retention at both 12 and 24 months postpartum [50]. Interventions showing high retention 
levels which were non-significant include; an enhanced intervention consisting of 8 peer 
mentor led sessions (4 ANC and 4 PNC) [52]. A cRCT of mother support groups [35], facility 
based versus community based peer support intervention [39],  and a culturally adapted 
cognitive-behavioural intervention(CBI) led by mentor mothers [36] showed no significant 
difference between arms.  
 
Maternal retention significantly improved in 4/5 mhealth interventions: maternal health 
information text messaging increased the number of ANC visits [32]; bi-directional text 
messaging resulted in improved attendance within 8 weeks post-delivery [47] but retention 
rates were low (19.6% intervention, 11.8% control); cellphone counselling improved retention 
at delivery and 6 weeks, but not 14 weeks, postpartum intervention compared to SOC arms 
[55]; and sending 14 messages during pregnancy and postpartum produced significant 
postpartum retention effects in the unadjusted model which did not persist when adjusted 
(Table 2) [48]. Cell phone based case management study showed high retention within 10 
weeks and at 12 months post-delivery but sample sizes were small in both arms (n=50 each) 
and the difference in retention between arms was not significant[56]. 
 
Integration of ANC and HIV services was not statistically significant in improving retention in 
the first 6 months after HIV-positive diagnosis [57] but was at 12 months [59]. A model of care 
involving a series of interventions over three years to enhance linkage between ANC and ART 
showed significantly improved effects at 6 months [60]. No effect was seen in a 3 arm study 
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of integrated MIP clinics and integrated MIP clinics plus text messaging reminders compared 
to SOC at 12 months postpartum[44].  
 
Both multicomponent  interventions showed significant differences between arms; 
combining POC CD4 testing, task shifting, integrated MIP services and male and community 
involvement, increased MIP retention in intervention groups at both 6 and 12 weeks 
postpartum in all models [30]; and providing individualised PMTCT education, overarching 
service and personal support, and text and calls to issue visit reminders, resulted in a lower 
attrition of MIPS at 6 months postpartum [34]. 
 
Perinatal case management to provide support and address barriers to care, showed women 
in the intervention arm were significantly more likely to be retained in HIV care 12 months 
postpartum compared to those not receiving the intervention [31]. Conditional cash 
incentives for attendance of clinic visits and acceptance of PMTCT services [62] showed a 
significant 13% improvement in retention at 6 weeks postpartum. 
 
CHWs for adherence counselling [46] and defaulter tracing [46, 58]  between delivery and 60 
to 120 days postpartum, CQI at 6 months postpartum [49] and point-of-care (POC) CD4 testing 
with CD4 count-specific adherence counselling[41] did not yield any significant improvement 





Figure 3: Effect of intervention type on retention in pregnant and postpartum women. Studies 




3.3.2 Pregnant women 
For studies exploring retention in pregnant women only, 2/3 were significant, with all 
assessing short retention. A strong association was found between couple’s HIV testing and 
counselling with male involvement at 1 month [61] and the Elombe SOP involving mentor 
mothers and defaulter tracing through text, calls and home visits showed women in 
intervention facilities were significantly less likely to miss second ANC visits [37] (Table 2 and 
Fig 4). A randomised pilot using a video based intervention showed no significant difference 
in retention at 1 month [42].  
 
 
Figure 4: Effect of interventions on retention in pregnant women. 
 
3.3.3 Postpartum women 
Five studies focused on postpartum women only, with varied interventions, time points, 
settings and retention definitions. Three improved retention: Mother to Mother Uganda 
showed peer support [40] significantly improved MIP retention in intervention groups across 
3 time points, 6 weeks post birth, 6 weeks post breastfeeding and at 18 months postpartum; 
integrated clinics for MCH services; integrated ART and MCH services improved 12 months 
postpartum maternal retention [63] and community outreach and paper based appointment 
tracking reported a net decrease of missed visits in intervention compared to control clinics 
at 6 months [53] (Table 2). However, for the latter recalculated ORs show those in the 
intervention were more likely to have missed visits that those in the control (Fig 5). Non-
significant but high retention levels were observed for interventions involving lay health 
worker home visits [38] and postpartum adherence clubs [45] at 18 and 6 months’ 




Figure 5: Effect of various interventions on maternal postpartum retention. Guillane 2017, a 
retrospective study with no control, is not presented. 
 
3.4 Adherence 
Pooled sample sizes for the 16 adherence studies were:  534 postpartum (n=2), 402 pregnant 
(n=2) and 4895 pregnant/postpartum women (n=12).   
 
3.4.1 Pregnant and postpartum women 
Table 4 demonstrates study reported effects and Fig 6 provides recalculated OR’s based on 
reported n/N’s for studies with controls. Overall, 2/12 interventions assessing adherence in 
pregnant and postpartum women showed statistically significant improvement in adherence: 
viral suppression was more likely before delivery, in the first 90 days post-delivery, and 12 
months postpartum for the case management intervention although significance was only 
seen in the unadjusted model for the latter 2 timepoints [31] and structured Mentor Mother 
support was, at 6 months postpartum, associated with a higher likelihood of viral suppression 
[54]. 
 
It is worth noting that many studies demonstrated adequate to high levels of adherence 
although these  were  non-significant: high self-reported adherence at pregnancy and delivery 
in both Mamekhaya (95%) and control sites (100%) were observed (Table 2) but samples sizes 
were small with high LTFU among those recruited at baseline[36]; at 6 months postpartum, 
women in facility- and community-based peer support showed high rates of viral suppression 
(87% and 81%) [39]; and task shifting managed by ART nurses and peer counsellors instead of 
doctors with less frequent visits at 6 to 12 months postpartum showed adequate adherence 
(88%) although control group adherence was higher (91%) [43]. A peer led sessions of 4 ANC 
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and 4 PNC actually showed women in the SOC were significantly more likely to adhere to ARVs 
at 1.5 months postpartum than those in the intervention [52].  
 
No significant improvement in adherence was found for: integrated care using self-report [57, 
59]; multicomponent interventions measured by VL at 6 months postpartum [34]; facility and 
community based peer support[39]; CHWs using MPR at 90 days postpartum[46] financial 
incentives using pill count and viral load at 6 weeks [62]; and cognitive behavioural risk 
reduction individual and group sessions using self-reported at 12 months [51]. 
 
3.4.2 Pregnant women 
Of the 2 studies evaluating improved adherence in pregnant women, a video intervention 
using pill count and self-report found a significant difference after 1 month when using a self-
reported adherence measure, but none when using electronic pharmacy pill count [42]. 
However, adherence was extremely low at 13.6 – 15.3%.  Using MPR, no association between 
cHCT and adherence measured by MPR was seen at 1-month post-ART initiation (Table 4 and 
Fig 7).  
 
3.4.3 Postpartum women 
Integration of ART and infant follow-up services showed a significant improvement in 
adherence measured by VL [63] for postpartum women. Adherence clubs showed no 
significant difference in viral suppression between arms at 3 time points but adherence levels 
were extremely high at 6 weeks (99%), 3 months (96%) and 6 months (95.2%) postpartum 
[45] (Fig 8).  
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Table 3: Characteristics of included studies for adherence in pregnant and postpartum women alphabetically by intervention type and author (n=16). 








POPULATION INTERVENTION DESCRIPTION CONTROL DESCRIPTION 
ADHERENCE CLUB 




VL <50, 50 - 1000 and >1000 
copies/ml 
6weeks, 3 and 6 months 
postpartum postpartum Described in retention table Described in retention table 
CASE MANAGERS 
Anderson, 2017 USA retrospective 2005 to 2013 VL ≤200 copies/mL closest to delivery during pregnancy 
HIV care engagement 
within 90 days’ post-
delivery and 12m 
pregnant women, 
postpartum, MIPS 
Described in retention table 
 Described in retention table 





April 2014 to 
March 2017 
Self-reported maternal ARV 
use 12 months  
‘Protect Your Family’ (PYF) participants 
received SOC PMTCT and lay health worker 
led group and individual theory-based 
social- group intervention sessions during 
pregnancy and postpartum. 
SOC PMTCT care and health 
videos to ensure SOC 
participants were at the 
facility for the same duration 
as intervention participants 
COMMUNITY HEALTH WORKERS 
Nance, 2017 Tanzania cRCT May 2015 to March 2016 
medication possession ratio 
(MPR) ≥ 95% 60 -120 days postpartum 
pregnant, 
postpartum Described in retention table Described in retention table 
COUPLES HIV TESTING AND COUNSELLING 




Adherence ≥90% within 33 
days (calculated by clinicians, 
as number of pills taken/ 
number of days elapsed) 
within 33 days post ART 
initiation pregnant Described in retention table Described in retention table 
FINANCIAL INCENTIVE 
Yotebieng, 
2016 DRC RCT 
April 2013 to 
August 2016 
pill count (100% adherence) 
and VL 
pill count monthly, VL at 
enrolment, delivery, 6 
and 8 weeks postpartum 
pregnant, 
postpartum Described in retention table Described in retention table 
MODEL OF CARE 
Myer, 2018 South Africa RCT 
June 2013 to 
December 2014 VL <50 and <1000 copies/ml 12 months postpartum postpartum Described in retention table Described in retention table 
Turan, 2015 Kenya cRCT June 2009 to March 2011 
self-reported maternal ARV 
use during pregnancy 
ARV use during 




Integrated care at ANC AND HIV care and 
treatment in the same clinic until 18 
months postpartum) 
 
ANC referral for HIV care at 
same facility but a different 
clinic 
Washington, 
2015 Kenya cRCT 
June 2009 to 
March 2011 
self-report, swallowed ARVs 
for PMTCT across 
antepartum, intrapartum, 
and postpartum periods 




Combined ANC, PMTCT, and HIV services 
in same clinic. Same clinician provided ANC 
and postpartum services including EID 
until confirmed infant HIV diagnosis or 
infant 18m old. HIV+ MIPs referred to long-
term care at facility's HIV clinic. 
routine ANC and PMTCT 
services per National 
Guidelines. Once diagnosed, 
HIV infected women given 
referral to HIV care. 
MULTICOMPONENT INTERVENTIONS 
Fayorsey, 2019 Kenya RCT 
Sep 2013 to 
2015 
 
women retained with VL 
<1000 copies/mL 6 months postpartum 
pregnant, 
postpartum 
Described in retention table 







Africa pilot cohort 2006 to 2007 
Medication use during 
pregnancy (unclear how 
measured, possibly from 
health records) 
6 months postpartum pregnant, postpartum 
Described in retention table 
 
Described in retention table 
 
Hosseinipour, 
2017 Malawi cRCT Not reported 
VL suppressed <1000 
copies/ml at 6m 6 months 
pregnant, 
postpartum 
Described in retention table 
 Described in retention table 
Richter, 2014 South Africa cRCT 
July 2008 to 
April 2010 
Mother took AZT from the 
28th week of pregnancy, or 
on HAART 
1.5 months post birth pregnant, postpartum Described in retention table Described in retention table 
Sam-Agudu, 
2017 Nigeria cohort 
April 2014 to 
September 
2016 
VS VL <20 copies/ml 6 months postpartum pregnant, postpartum, MIPS Described in retention table Described in retention table 
TASK SHIFTING 
Kiweewa, 2013 Uganda RCT 
May 2007 to 
September 
2009 
VL < 400 copies/ml 6 – 12 months post ART initiation 
pregnant, 
postpartum 
Less frequent visits mostly managed by 
ART nurse and peer counsellor, ART nurses 
managed most follow-up visits at longer 
intervals between visits, patients 
supported by peer counsellors and home 
visiting 
SOC (monthly ART care by 
doctor, routine counselling 
by certified nurse counsellor. 
No home visits in case of 
missed visits. 
VIDEO 




electronic pharmacy pill 




Table 4: Results and effect sizes reported by included adherence studies in pregnant and postpartum women by intervention. 
AUTHOR LENGTH OF FOLLOW UP 
POPULATION 









 Combined <1000 copies at 6 weeks 80/81 (99%) 42/42 (100%) 
Not reported, p=0.483 Serious€ Combined <1000 copies/ml 3 months postpartum 75/78(96%) 35/36(97%) 







HIV+ postpartum and HIV 
exposed infants 
 
VL ≤200 copies/mL closest to delivery during ANC 301/448 (67.2%) 167/401 (41.7%) OR 3.02 95% CI 2.26-4.05, p < 0.0001 aOR 1.90 95% CI 1.33-2.71, p = 0.0005 
Serious€ 
 min one VL or CD4 count test in first 90-days after delivery 192/448 (42.9%) 142/401 (35.4%) 
OR 1.36 95% CI 1.03-1.80, p = 0.029 
aOR 1.21 95% CI 0.88-1.65, p = 0.236 
VL ≤200 copies/mL at 12 months post-delivery 184/448 (41.1%) 119/401 (29.7%) OR 1.73 95% CI 1.30-2.30, p = 0.0002 aOR 1.26 95% CI 0.90-1.77, p =0.178 
COGNITIVE BEHAVIOURAL RISK REDUCTION 
Ramlagan, 
2019 
12 months after 
birth 
HIV+ 8 - 24 weeks 
pregnant and postpartum self-reported maternal adherence to ART 143/196 (72.9%)  202/220 (91.8%)  Not reported 
Some 
concerns§ 
COMMUNITY HEALTH WORKERS 
Nance, 2017 90 days postpartum HIV + pregnant and postpartum, MIPS MPR ≥ 95%   41/138 (29.7)  39/164 (23.8%)   Not reported High§ 
COUPLES HIV TESTING AND COUNSELLING 
Wesevich, 
2017 1 month HIV+ pregnant women 
Adherence ≥90% within 31 days (calculated by clinicians, 
as number of pills taken/ number of days elapsed) 76/110(69%) 32/48(67%) 
RR 1.04 95%CI 0.82 – 1.31, p= 0.8 





8 weeks postpartum 
 
newly diagnosed HIV+ ≤32 
weeks gestational age 
 
Adherence to ARVs based on pill count 109/156 (69.9%) 96/141 (68.1%) 
RD 0.02 95%CI -0.06 to 0.09, p not reported 





6 weeks postpartum VL, undetectable 113/171 (66.1%) 108/155(69.7%) risk difference, -0.04; 95% CI: -0.14 to 0.07, P Not reported 
MULTICOMPONENT INTERVENTIONS  
Fayorsey, 
2019  
6 months HIV+ starting ANC  
women retained with VL <1000 copies/mL 99/170 (58.2%) 86/170 (50.6%) RR 1.1.5 95% CI 0.95–1.40, p = 0.16 
Low¥  
women retained with VL < 40 copies/ mL 84/170 (49.4%) 69/170 (40.6%) RR 1.22 95% CI 0.96–1.54, p = 0.10 
MODEL OF CARE 
Myer, 2018 12  months postpartum HIV+ postpartum  <1000 copies/ml 162/202 (780%) 142/209 (68%) Not reported, p = 0.005 Low¥ 
Turan, 2015  6 months postpartum 
HIV+ pregnant  
 
self-reported ARV use during pregnancy 138/173 (80%) 75 /152 (49%) OR 4.05 95% CI 2.00 to 8.00, Not reported 
High§ 
 self-reported ARV use during labour and delivery 28/173 (16%) 84/152 (55%) OR 0.16 95%CI 0.04 to 0.68, Not reported 
self-reported maternal and infant ARVs use post birth 22/173(13%) 57 /152 (38%) OR 0.24 95%CI 0.08 to 0.70, Not reported 
Washington, 
2015 
12 months after 
enrollment  
HIV+ pregnant  
 
Self-report of swallowed ARVs across antepartum, 






  Self-report of swallowing only intrapartum and 





6 months post 
delivery HIV+ pregnant  
Self-report used medication during pregnancy  38/40 (95%) 31/31 (100%) Not reported 
Serious€ 
Sel-report used medication during delivery  37/40 (92.5%) 30/31 (96.8%) Not reported 
Hosseinipour, 
2017 6 months HIV+ pregnant  
VL < 1000 Copies/ml FBPS 237/274(87%) 
208/247 (84%) Not reported, p = 0.20 High§ 
VL < 1000 Copies/ml CBPS 254/312 (81%) 
Richter, 2014 1.5 months post delivery HIV+ pregnant  
Mother took AZT from 28th week of pregnancy, or on 
HAARTa 
340/377 (90.2%) 445/466 (95.5%) OR 0.44 95% CI 0.26 - 0.74, p = 0.002  High§ 
Sam-Agudu, 
2017 
up to 6 months 
postpartum HIV+ pregnant, MIPS VL <20 copies/ml for women with VL results available 108/176 (61.4%) 22/48 (45.8%) 
OR = 7.4 95% CI 3.8 - 14.5, significant c 





6 to 12 months post 
ART initiation pregnant and postpartum  VL < 400 copies/Ml  38/43 (88%) 29/32 (91%) 
Difference (95% CI) -0.03 (12% to 11%),  






HIV+ pregnant not on ART 
 
electronic pharmacy pill count > 90–100% 95/146 (65.1) 95/160 (59.4) Not reported, p =0.31 
High¥ 
 
Self-reported adherence at one-month: missed dose in 
past 7 days 16/117 
b (13.6%) 34/127 b (26.8%) Not reported, p =0.02 
Self-reported adherence at one-month: missed dose in 
past 30 days 18/117 
b (15.3%) 38/127 b (29.9%) Not reported, p = 0.02 
€ROB assessed via ROBINS II 
§ ROB assessed via ROB 2 for cluster randomised trials 
¥ ROB assessed via ROB 2 for individually randomised trials 
a.  unclear how this was measured, possibly extracted from health records 
b. calculated denominator 
c.  indicated as significant, but p-value not reported 
d. indicated as non-significant, but p-value not reported 
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Figure 7: Effect of intervention on ART adherence in pregnant women, across various time 





Figure 8: Effect of intervention on ART adherence in postpartum women, across various time 
points and adherence measures. 
 
3.4.4 Adherence measure categories 
Five studies used objective measures, 5 subjective measures and 6 used biological correlates 
of VL to assess adherence (Table 4 and Fig 9), with some studies using more than 1 measure 
to assess adherence. Fig 9 indicates that the subjective self-report measures favours the 
control, but the objective adherence measures and VL favours intervention.  
 
Objective measures included electronic pharmacy pill count (n=3), and medication possession 
ratio (n=2). All cut offs across measures was at ≥90% adherence except for one study using 
proportion of days covered which used ≥80%. The only subjective measure used was self-
report, without specification of the tools used, where women reported ARV usage across a 
wide range of time points; during pregnancy (n=1), labour(n=1), delivery (n=1), postpartum 
(n=1), 1.5 months after birth (n=1), 6 months postpartum (n=1) and 12 months postpartum 
(n=1). All studies involving adherence self-report after an intervention involved pregnant 
women followed up in to postpartum.  
 
Eight studies used VL as a biological correlate to measures adherence in pregnant and 
postpartum women. Cut-offs were wide ranging at <20, <40, <50, 50 – 1000, ≤200, <400, 
<1000 copies/mL and undetectable VL with some studies measuring adherence at multiple 
cut-off points. Time points at which VL was assessed were also wide ranging from within 90 
days post-delivery (n=1) 6 weeks (n=2), 3 months (n=1), 6 months(n=5) and 12 months (n=3). 
The most common time point and VL cut-off used across adherence studies was 6 months 
and <1000 copies/ml respectively. Two studies focused on postpartum women, and the 




Figure 9: Recalculated effects sizes of study interventions outcomes categorised by adherence 
measures categories and cut-offs. 
 
3.5 Risk of Bias 
Eight of 15 cRCTs were of high risk, 7 had some concerns and none were of low risk (Figs 10a, 
10b and 11). High risk resulted from timing of identification and recruitment of participants 
after cluster randomization and lack of information on randomization method and lack of 
blinding. Three of the 7 RCTs were of low risk, 4 were rated as having some concerns, and 
none were of high risk. Similar to cRCTS bias arose from lack of blinding and allocation 
concealment information. Using ROBINS-I, 2 studies were of moderate risk, 8 of high risk and 
1 of critical risk of bias, arising mainly from confounding, selection of the reported result and 
lack of information on intervention deviations (Figs 12a and 12b). No studies were excluded 




10a.                               
10b.       
Figure 10: Risk of bias assessment for randomised control trials using ROB 2 by a) study and b) 
weighted plots by domain. 
 
Figure 11: Risk of bias assessment for studies with a cluster-randomised and stepped wedge study 
design using ROB 2. Diagrams were generated with the official ROBVIS tool, which does not generate 




12a.                                       
12b.   
Figure 12: Risk of bias assessment for non-randomised control trials using ROBINS by a) study 
and b) weighted domain. 
 
3.6 PRECIS-2 
The majority of PRECIS-2 scores were between pragmatic and equally pragmatic/explanatory 
on the continuum (Table 6). Average scores for each study indicated that all were either 
equally pragmatic and explanatory (scores 3.0 to 3.9) or pragmatic (scores 4.0 to 5.0), except 
for a cHTC study that was rated 2.9 at the explanatory level (scores 1 to 2.9).  
 
Analysis by intervention type showed that two SMS based maternal health interventions, a 
video intervention and multicomponent interventions were equally pragmatic and 
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explanatory while integrating of MCH services, financial incentives and a structured peer 
mother program were the most pragmatic. The only study scored as rather explanatory was 
a cHTC study, involving one facility, recruitment of males by invites and specific study tracing 
and follow-up. Overall 18 studies were scored as rather pragmatic to implement in practice. 
 
3.7 Ongoing studies identified 
The search process identified 18 ongoing RCTs with our relevant outcomes (S3 Table). This list 
is non-exhaustive consisting of 14 ongoing studies exploring retention, and 13 assessing 
adherence in pregnant and postpartum women. Intervention types are varied including: a 
smartphone application; video; electronic pill container triggering text messaging if 
unopened; peer support (n=6); male involvement and couples counselling (n=2); 2 CQI 
interventions and text message interventions each; a behavioural parenting programme; 
depression support group and group counselling; an adherence club, and community leader 
engagement. Outcome assessment time points ranged from 3 to 24 months. 
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Table 5: Mean PRECIS-2 scores of for each study and across domains. 

















Analysis Mean (SD) 
Wesevich 2017c cHCT 4 2 1 2 2 2 3 5 5 2.9 (1.5) * 
Coleman 2017a mHealth 4 NA 5 1 2 3 4 5 3 3,4 (1,4) * 
Kim 2019c video 2 5 5 1 4 NA 2 5 4 3,5 (1,6) 
Ross-Degnan 
2017c 
Appointment tracking 3 5 5 3 1 4 3 5 3 3.6 (1.3) 
Fayorsey 2019c Multicomponent 4 5 5 1 2 3 2 5 5 3,6 (1,6) * 
Nance 2017c CHWs 4 NA 3 2 4 4 4 5 3 3,6 (0.9) 
Sarna 2019a mHealth 3 5 5 2 3 4 2 5 4 3.7 (1.2) 
Odeny 2014a mHealth 3 5 5 2 2 4 3 5 4 3,7 (1.2) * 
Richter 2014c Peer Support 5 5 3 2 2 4 3 5 4 3,7 (1,2) * 
Gill 2018a Multicomponent 4 5 5 2 2 3 3 5 5 3,8 (1,3) * 
Odeny 2019a mHealth 5 5 3 2 2 4 3 5 5 3,8 (1,3) * 
Oyeledun 2017a QI 4 4 4 1 1 5 5 5 5 3,8 (1,6) 
Aliyu 2016a Multicomponent 4 5 5 1 2 4 4 5 5 3,9 (1,5) * 
Hosseinipour 
2017c 
Peer Support 5 5 5 2 3 3 4 5 3 3,9 (1,2) 
Myer 2017c Adherence Club 2 5 5 3 4 4 3 5 4 3,9 (1,1) 
Turan 2015c Model of Care 5 5 4 1 1 5 4 5 5 3,9 (1,7) 
Weigel 2012a Model of Care 5 5 5 1 1 5 4 5 4 3,9 (1,7) 
Foster 2017a Peer Support 5 5 5 2 2 2 5 5 5 4,0 (1,5) 
Joseph 2017a POC CD4 testing and count–
specific adherence 
counselling 
5 5 4 1 2 NA 5 5 5 4,0 (1,6) 
Phiri 2017a Peer Support 5 5 5 2 3 3 4 5 4 4,0 (1,1) 
Schwartz 2015a mHealth 4 5 3 3 3 4 4 5 5 4,0 (0,9) 
Vogt 2015a CHWs 5 5 5 3 3 4 2 5 4 4,0 (1,1) 
Washington 
2015c 
Model of Care 5 5 5 1 1 5 5 5 5 4,1 (1,8) 
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Analysis Mean (SD) 
Mwapasa 2017a Model of Care 3 5 5 3 4 4 4 5 5 4,2 (0,8) 
Ramlagan 2019b cognitive behavioural risk 
reduction 
4 5 5 3 2 5 5 5 4 4,2 (1,1) 
Yotebieng 2016c Financial Incentive 5 5 5 3 3 2 5 5 5 4,2 (1,2) 
Anderson 2017c Case managers 4 5 5 5 5 3 2 5 5 4,3 (1,1) * 
Futterman 2010c Peer Support 5 5 5 3 2 5 5 5 4 4,3 (1,1) 
Igumbor 2019a Peer Support 5 5 5 3 4 4 3 5 5 4,3 (0,9) * 
Kiweewa 2013b Task shifting 3 5 5 3 4 4 5 5 5 4,3 (0,9) 
Guillaine 2017a Multicomponent 5 NA 3 3 5 5 4 5 5 4,4 (0,9) 
Sam-Agudu 
2017c 
Peer Support 5 5 5 3 3 4 5 5 5 4,4 (0,9) * 
Myer 2018c Model of Care 3 5 4 4 5 5 5 5 5 4,6 (0,7) * 
Mean (SD) 
 
4,2 (1.0) 5,0 (0.2) 4,6 (0.8) 2,3 (1.0) d 2,8 (1.2) d 4,0 (0.9) 3,8 (1.1) 5,0 (0.0) 4,4 (0.7) 3.9 (1.2) 
Scores: 1 = Very explanatory, 2 = Rather explanatory, 3 = Equally pragmatic/explanatory, 4 = Rather pragmatic, 5 = Very pragmatic. 
a. Retention  
b. Adherence 
c. Retention and adherence  
d. Explanatory  
e. Pragmatic 




This systematic review identified 33 studies assessing the effect of interventions on retention 
in care and adherence to ART during ANC and PNC, with none identified for ICC or PCC periods. 
All published articles were conducted between 2010 and 2019, the most (n= 14) being in 
2017, possibly related to earlier recommendations highlighting the need for tailored 
interventions [2, 6, 10] for these population groups.  
 
All interventions were conducted in sub-Saharan Africa, except one from the USA. This 
absence of regionally diverse data is surprising given that countries in Asia such as Thailand, 
India and China have high numbers of PLWHIV [64]. It is possible our search strategy may have 
not identified these studies, however ongoing studies show a similar pattern. Intervention 
types were varied and significant heterogeneity was found in intervention complexity, study 
design, outcome definition, outcome measurement, assessment time points, as well as 
intensity and duration of follow-up.  
 
The majority of interventions recruited women during ANC and followed them through to the 
postpartum period, varying over duration of follow-up and time points. Peer support, 
mhealth, models of care, multicomponent interventions, financial incentives, cHCT and case 
management significantly improved retention, in contrast to one peer support, model of care 
and case management intervention each which were associated with significantly improved 
adherence. 
 
Although the most frequent intervention type, only one peer support intervention [54] 
recruiting women during ANC with follow-up into postpartum, demonstrated significant 
benefit, involving relatively short term retention at 6 months postpartum and finding low 
retention estimates (61.9%). Considering the postpartum period, one peer support mentor 
mother intervention with large MIPS sample sizes showed significantly high levels of retention 
at 6 weeks after birth, 6 weeks after cessation of breastfeeding and long term at 18 months 
post-delivery [40]. Although reduced retention was still observed along these time points, the 
study shows promise as a successful intervention for adoption and scale up. Following up 
women at different time points from short to longer term can uncover finer granularity in 
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early patterns of retention [65]. Peer support can promote care seeking behaviour by 
addressing psychosocial barriers to care and stigma [66] but privacy concerns could be a 
hindrance to wide scale implementation [67]. 
 
mHealth, particularly text messaging and cellphone counselling, showed promise as a strategy 
to improve retention with almost all demonstrating significantly improved outcomes and high 
retention estimates ranging from 82.2% to 95.2%, although these were at short term 
retention periods. Twice-weekly text messages relevant to pregnancy stage also improved 
ANC retention although sample sizes were small [32]. Bi-directional text messaging and calls 
between women and the facilities also improved short term retention levels at 8 weeks post-
delivery [48]. However, issues such as overt or covert content of text messages [68] for those 
who share phones and the uncertainty of whether women actually read messages sent [69] 
require further examination given the challenges of time and stigma this population cite as 
barriers to care. Another intervention showing improved short term retention at delivery and 
6 weeks postpartum was cellphone counselling [55]. Retention at the 14 week timepoint for 
this same study was not significant but still high at 83.3% but as expected displayed a drop in 
retention compared to the earlier timepoints. More evidence is needed at long-term 
retention points for this intervention type. 
 
Almost all multicomponent interventions showed significantly improved effects (ranging from 
75% to 83%). However, this was again at mainly short-term retention timepoints. A 
significantly large effect size was seen on MIP retention at 6 and 12 weeks in rural Nigeria 
after a combined package of task shifting from doctors to nurses midwives and CHWs, POC 
CD4 testing, integrated mother and infant care, family or male partner participation in care 
and community engagement [30]. Other multicomponent interventions [34, 37] used varied 
combinations of lay counsellors or mentor mothers to provide phone and text visit reminders, 
defaulter tracing by home visits, counselling, home or clinic PMTCT health education. This led 
to decreased MIP attrition 6 months postpartum [34] and improved retention in early ANC 
[37] - however the latter used small sample sizes and only measured outcomes between the 
first and second ANC visit making it too weak to base recommendations on. Even though not 
significant, another study demonstrated high long-term 18-month retention (99.5%)[38]. 
While demonstrating improvements, this intervention type could be resource intensive and 
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logistically costly, and scored on the less pragmatic side of the PRECIS-2 scale. Nevertheless, 
it remains a valuable strategy with potential for improving retention in both pregnant and 
postpartum women in the short and longer term, with more work needed on the latter. 
 
The impact of integration of services as a model of care intervention on retention remains 
uncertain based on gathered evidence. PNC integration of MCH and ART service showed 
significantly higher retention 12 months postpartum and was scored most pragmatic for real 
world settings, highlighting its potential for further study and adoption. This is different from 
earlier studies of integration of ANC and ART care in Kenya [57, 59] which did not echo this 
finding. This may be due to the heterogeneity in context, content of services, type of staff 
delivering services (nurse-midwives versus clinicians), and retention or loss-to-follow-up 
definitions. Another model of care aiming to improve linkage of service between ANC and 
ART clinics showed significantly improved 6-month retention relative to the control but at low 
levels (65%) with the study itself showing critical ROB. While service integration targets 
multiple barriers to ANC, PNC and HIV care such as cost and time constraints, Turan et al. 
2015 [57] question whether integration of HIV care may place additional burdens on already 
overworked, under resourced HCWs and poor infrastructure [57, 70]. One study [44] 
encountered resistance during implementation from HCWs due to increased workloads 
resulting from integration, which was resolved in part by incentives.  However, for scale up 
and implementation this would not be sustainable. Women have also raised concerns about 
service integration leading to overcrowded facilities and mothers and infants both being 
attended to on visit days [71].  
 
One intervention using financial incentives [62], which increased at each subsequent visit, 
significantly improved retention at 6 weeks postpartum, for women recruited during ANC. 
This intervention type may address patient level costs barriers to visit attendance, although 
the health system cost may be a hindrance to scale up in certain contexts. 
 
Case management during ANC and postpartum [31] appointment tracking postpartum [53], 
and cHTC during pregnancy [61] are also worthy strategies to consider to improve maternal 
retention. The case management intervention while rated as high ROB and showing moderate 
retention levels (52.7%) 12 months postpartum in the USA, may be valuable in that case 
36 
 
managers provided referrals, psychosocial support and address individual barriers to care. 
Since not all pregnant and postpartum women will face the same set of challenges, this 
intervention offers individually tailored support.  
 
It is worth noting that, although non-significant, many studies looking at long-term time 
points showed high levels of retention. This is important given the absence of assessment of 
long term retention noted in previous reviews [5, 20]. Peer support [50] was assessed long 
term at 12 and 24 months, although this was post-ART initiation and not postpartum, showing 
high retention (80.9% and 83.7%). Surprisingly 24-month retention was higher than that at 12 
months. Similarly, almost 100% retention at 18 months postpartum was found in an 
multicomponent intervention [38]. While single interventions showed promised, they may be 
insufficient individually to promote improved maternal health outcomes. Combined 
interventions could be the answer but more evidence is needed to make definitive 
recommendations. 
 
Overall, the evidence for interventions to improve adherence in pregnant and postpartum 
women were weak. More interventions focussed on improving retention in care rather than 
ART adherence in our populations of interest (33 versus 16 studies respectively). Fourteen 
studies assessing retention assessed ART adherence as well, but only 2 explored adherence 
specifically. While retaining pregnant and postpartum in care is important there is a 
distinction between women attending visits [65] and actually being ART adherent. Said 
another way “adherence” to scheduled visits does not translate to adherence to ART, so this 
finding highlights the need for more interventions to improve ART adherence particularly 
since only 3 studies demonstrated >90% adherence[36, 45, 52] and 4 showed ≥80 – 90 % 
adherence[39, 43, 57], none of which were significant. Using VL data, integration of services 
[63], case management at delivery and 12 months post-delivery [31], and structured peer 
support programs [54] showed significantly improved adherence but these were at low levels 
(41.1% to 78%). However, these 3 interventions were also those that produced a significant 
effect on retention. This indicates that use of these intervention types may serve a dual 




A few peer support interventions demonstrated >90% adherence with one finding women in 
the SOC were significantly more adherence than those in the intervention [52]. Task shifting 
[43] and cognitive behavioural risk reduction[51] were 2 interventions exploring adherence 
only at between 6 to 12 months. While neither were significant both showed high adherence 
in the control compared to the intervention groups, one using VL [43] and the other self-
report [51]. 
 
In terms of adherence measures, most studies used VL as a biological correlate to assess 
adherence although self-report usage was also high. Studies using the latter subjective 
measure did not specify the tools used for self-report or whether these were validated, adding 
another layer of variability to a measure that is already inconsistent due to its high risk of 
social desirability and recall bias.  
 
The need for standardized measures for cross comparability and reproducibility, and evidence 
of long-term efficacy has been underscored before for both retention [72] and adherence [3] 
yet based on our review this remains largely unchanged. Moving forward this issue requires 
attention to inform protocols for future intervention studies in these populations. 
 
4.1.1 Application of interventions to real world settings 
All interventions, regardless of broad groupings, differed by rating levels but remained 
between pragmatic and equally pragmatic/explanatory on the PRECIS-2 score spectrum, 
indicating acceptable levels of applicability to real world settings.  
 
Scores were likely due to the fact that almost all studies were rated pragmatic or rather 
pragmatic for “Eligibility”, Recruitment”, “Setting”, “Outcome” and “Analysis” domains. The 
most explanatory domains were “organization” and “flexibility in delivery”, due to the varied 
interventions and their contrast to controls. The varied follow-up periods, and intervention 
struture are most likely reasons for the lack of trends observed for each intervention type. 
For example, some peer support interventions required follow-up by home visit and calls 
more frequently, on more structured formats than others. Other studies required more in-
depth, regular supervision and training of peer mentors while others involved once off 




Integration of care interventions displayed on average a more pragmatic score while most of 
the mhealth interventions fell on the equally pragmatic/explanatory side of the scale, 
probably due to the organization needed to produce relevant text message content and 
resources required to deliver the intervention i.e. platform for delivery, mobile phones for 
patients, literacy, airtime for patients and HCWs. The only interventions rated as explanatory 
was the cHCT intervention with male involvement, possibly due to its specific recruitment 
strategy, organization required for issuing invitations, and the level of follow-up employed. 
Rating results suggest that integration of care, peer support, multicomponent interventions 
and task shifting may be the most pragmatic interventions to implement. 
 
4.1.2 Duration of intervention effects 
Previous reviews [20, 72] noted that there were few interventions exploring retention 
postpartum period and what did exist was contained to the first 3 months after delivery. This 
review identified more interventions spanning pregnancy into postpartum as well as only the 
postpartum period, with most studies assessing intervention effect on retention at 6 months 
postpartum. Some studies assessed outcomes 6 to 12 months postpartum and others at that 
time point post-ART initiation. Only 3 studies assessed retention long term, 2 at 18 months 
and 1 at 24 months indicating these postpartum retention times should be explored further 
to understand maternal patterns long term. ICC and PCC interventions could also address this 
period after 24 months to assess maternal patterns of retention and adherence. 
 
4.1.3 Future studies 
Based on ongoing studies, examination of interventions to improve retention and ART 
adherence in pregnant and postpartum women is gaining momentum. This review only 
identified 33 studies over 3 decades that met our inclusion criteria yet 19 studies over the last 
few years alone – based on a non-exhaustive search - are now being conducted. This bodes 
well for identifying more robustly tested interventions over various short and long-term 
retention periods and adherence measures demonstrating that there will be continued future 




4.1.4 Knowledge gaps 
Knowledge gaps identified include the absence of ICC and PCC intervention assessments, and 
is concerning in the light of universal life long ART where women need to remain in care and 
sustain ART adherence, not just during, but after and in between pregnancies. Examination 
of long-term ICC and PCC interventions especially, could generate valuable retention and 
adherence results on which to base implementation and scale-up. Interventions that show 
promise such as case management require more examination in varied settings as does other 
interventions only assessed in Sub-Saharan Africa. This is key to allow generalizability of 
interventions to other contexts. Cost effectiveness of recommended interventions will also 




Review limitations include conducting searches in English, as well as restricting our inclusion 
criteria to studies with retention or adherence as a primary or secondary outcome which may 
have led to relevant studies being missed. Although no geographic restrictions were placed 
and multiple databases searched all but one of included studies was from Sub-Saharan Africa, 
limiting generalizability of interventions in varied settings. The use of one reviewer for data 
extraction may have impacted the scientific rigor of this process. Given that successful 
interventions in one context does not guarantee effectiveness in others with their unique 
resource availability, behavioural and social variabilities, selection of interventions for 
adoption and scale up in routine care need to be carefully evaluated. Further the large degree 
of heterogeneity in intervention type, study design and conduct, outcome measurements and 
definitions, and duration of follow up precluded the ability to conduct subgroup and a meta-
analysis. Studies with small sample sizes may have been inadequately powered. 
 
4.1.6 Conclusions 
Although there is evidence that interventions identified, particularly combination 
interventions, can significantly improve our outcomes of interest, no one intervention 
demonstrated this absolutely as each intervention type also demonstrated no effect on 
improving outcomes. Multicomponent interventions, mhealth and integration of services are 
40 
 
highlighted as promising interventions to guide strategies aimed at improving retention in 
care and ART adherence in pregnant and postpartum women.  
 
Studies with significantly improved, or high non-significant levels of retention, did not persist 
with time, demonstrated by retention drops with increased length of postpartum, in keeping 
with the trends described in the literature. Interventions effective to sustain long-term 
retention are thus needed particularly in the context of universal lifelong ART. This also 
highlights the gap for ICC and PCC interventions which would address the intermediate period 
between pregnancies for HIV-positive women. Almost all interventions were scored as 
pragmatic to implement in real world practice, but the evidence base requires strengthening 
for outcomes in our populations of interest, which seems a possibility given the number of 
ongoing studies identified.  
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6 SUPPORTING INFORMATION 
 




Search ((HIV [MeSH Terms]) OR HIV Infections [MeSH Terms]) OR ((HIV OR HIV-1 OR HIV-2 
OR HIV1 OR HIV2 OR Human Immunodeficiency Virus OR Human Immunedeficiency Virus 
OR Human Immune-Deficiency Virus OR Human Immuno-Deficiency Virus OR Acquired 
Immunodeficiency Syndrome OR Acquired Immunedeficiency Syndrome OR Acquired 
Immuno-Deficiency Syndrome OR Acquired Immune-Deficiency Syndrome OR Nevirapine 
OR Zidovudine)) 
#2 
Search ((Antiviral Agents [MeSH Terms]) OR Antiretroviral Therapy, Highly Active [MeSH 
Terms]) OR ((anti-AIDS OR anti-HIV OR anti HIV OR antiretroviral OR anti-retroviral OR anti 
retroviral OR HAART)) 
#3 
Search ((((Pregnancy [MeSH Terms]) OR Pregnant Women[MeSH Terms]) OR Postnatal 
Care[MeSH Terms]) OR Postpartum Period[MeSH Terms] OR Preconception Care[MeSH 
Terms]  ) OR ((pregnant OR antenatal OR interconception OR postnatal OR perinatal OR 
postpartum OR preconception OR prenatal OR mother-to-child OR MTCT OR mother-to-
infant OR maternal-infant transmission OR PMTCT)) 
#4 
Search ((((Treatment Adherence and Compliance [MeSH Terms]))) OR Lost to Follow-Up 
[MeSH Terms]) OR ((adherence OR engagement OR care acceptor OR compliance OR patient 
acceptance OR retention OR loss to follow up OR lost to follow-up OR lost to follow up OR 
linkage to care OR pharmacy refill OR self-report OR electronic device monitoring OR plasma 
drug levels)) 






S2 Table. Excluded Studies with reasons (n=91) 
 
AUTHOR  YEAR REASON FOR  EXCLUSION 
Adeyemo 2013 Case series 
Akinde 2019 Interview 
Audet 2017 Full paper could not be located 
Audet 2018 Protocol 
Awiti 2016 Ongoing study 
Besada 2016 Interview 
Carmone 2014 Incorrect outcome 
Cataldo 2017 Qualitative study 
Chetty 2018 Author emailed, study results analysis is ongoing 
Ciampa 2011 Incorrect outcome 
Clouse 2018 Incorrect outcome 
Cowan 2015 Protocol 
Davey 2012 Incorrect population 
Dean 2012 No data 
Delva 2010 Therapeutic intervention 
DiCarlo 2018 Qualitative study 
Drake 2017 Protocol 
Ezeanolue 2015 Incorrect population 
Fairbanks 2018 Qualitative study 
Fayorsey 2016 Duplicate study data 
Feinstein 2015 Incorrect population 
Finocchario-Kessler 2014 Incorrect population 
Finocchario-Kessler 2019 Protocol 
Gamell 2017 Incorrect outcome 
Geldsetzer 2019 Incorrect population 
Gross 2015 Incorrect population 
Hanrahan 2019 Incorrect population 
Heinemann 2017 Duplicate study data 
Jaffer 2016 Dissertation 
Joseph Davey 2016 Incorrect population 
Kalembo 2013 No intervention 
Kassaye 2016 Primary or secondary outcome not relevant 
Kebaya 2014 Incorrect population 
Kieffer 2015 Ongoing 
Kim 2012 No response from author 
Liu 2014 Incorrect outcome 
Lund 2015 Incorrect population 
Mangwiro 2012 Protocol 
Masereka 2019 No intervention 
Mushamiri 2014 Incorrect population 
Napua 2016 No data 
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Namukwaya  Incomplete data, no author response 
"Friends for Life Circles for Option B Plus." 
* 
2015 Ongoing study, reported in S4 
"Improving ART Retention and Adherence 
in Uganda: the WiseMama Study." * 
2015 Ongoing study, reported in S4 
"Mobile Strategies for Women's and 
Children's Health: optimizing Adherence 
and Efficacy of PMTCT/ART." * 
2015 Ongoing study, reported in S4 
"Postpartum Adherence Clubs to Enhance 
Support: the PACER Study." * 
2015 Duplicate study data 
Nct. "Kenya Enhanced Mentor Mother 
ProgrAm (EMMA)." * 
2016 Ongoing study, reported in S4 
"Postpartum Adherence Clubs for 
Antiretroviral Therapy." * 
2017 Ongoing study, reported in S4 
"Support for Perinatal Adherence and 
Depression." * 
2017 Ongoing study, reported in S4 
"A Stigma Reduction Intervention at Time 
of Entry Into Antenatal Care to Improve 
PMTCT Services in Tanzania 
2018 Ongoing study, reported in S4 
"Developing and Assessing a Male 
Engagement Intervention in Option B+ in 
Malawi." * 
2018 Ongoing study, reported in S4 
"VITAL Start: brief Facility-based Video 
Intervention." * 
2018 Duplicate study data 
"A Peer-Led Intervention to Improve 
Postpartum Retention in HIV Care." * 
2019 Ongoing study, reported in S4 
"Adaptation of the Friendship Bench 
Intervention for HIV-infected Perinatal 
Women in Lilongwe." * 
2019 Ongoing study, reported in S4 
"CareConekta: a Smartphone App to 
Improve Engagement in HIV Care." *  
2019 Ongoing study, reported in S4 
"Peer Support to Mitigate the Impact of 
Stigma in Young HIV+ Pregnant & 
Postpartum Women." * 
2019 Ongoing study, reported in S4 
"Storytelling to Increase Family Support 
for Pre Exposure Prophylaxis Use." * 
2019 Incorrect population, included HIV negative 
women 
Odayar 2019 Protocol 
Odeny 2018 Protocol 
Oyeledun 2014 Protocol 
Pellowski 2019 Review 
Peltzer 2017 No response from author 
Pfeiffer 2017 No response from author 
Phillips 2019 No intervention 
Potter 2019 Incorrect outcome 
Puchalski Ritchie 2019 Review 
Reimers 2018 Incorrect population 
Reimers 2016 Protocol 
Reynolds 2016 Incorrect population 
Rosenberg 2015 Incorrect outcome 
Rosenberg 2014 Protocol 
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Rotheram-Borus 2011 Protocol 
Rotheram-Borus 2014 Data not provided from author 
Sam-Agudu 2017 Protocol 
Sando 2014 Protocol 
Shroufi 2013 No data 
Stein 2017 Ongoing reported in S4 
Toro 2012 Review 
Uwimana 2013 Incorrect population 
van Lettow 2014 No intervention 
van Lettow 2019 No response from author 
Wagner 2019 Protocol 
Wanga 2019 No data 
Watt 2019 Protocol 
Weiss 2014 Incorrect outcome 
Wesevich 2020 Incorrect outcome 
Williams 2014 Cannot locate 
Woelk 2016 Protocol 
Wong 2006 Incorrect population 
Yotebieng 2017 Protocol 
Yotebieng 2016 Duplicate study data 
Zunza 2017 Incorrect outcome 
Zuyderduin 2009 Incorrect population 
*  No primary authors listed in search results since this is still ongoing
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S3 Table. Ongoing RCTs (n=19) identified not included in this review 
 





assessmen timepoints Intervention Control 
CareConekta: A Smartphone App to 
Improve Engagement in HIV Care 2019 South Africa 
Retention and 
viral suppression 6 months after delivery 
CareConekta smartphone application enrolling pregnant 
women, plus text notifications mobility tracking, opt-in to 
phone calls, WhatsApp messages, advice on medication 
supply and nearby facilities when travelling 
Standard CareConekta, 
tracking mobility with no 
additional features. 
A Stigma Reduction Intervention at 
Time of Entry Into Antenatal Care to 





3 months after enrollment 
Video and brief counselling addressing HIV stigma at ANC, 
stigma-based counselling sessions for HIV+ women, 
building on video content. 
SOC 
Mobile Strategies for Women's and 
Children's Health: Optimizing 
Adherence and Efficacy of 





2 years postpartum 
unidirectional SMS vs. bidirectional text messaging 
between participant and provider for pregnant HIV+ 
women 
no SMS 
Cluster randomised trial to evaluate 
an intervention for depressed HIV-
positive women in the perinatal 
period, to enhance child 
development and reduce maternal 
depression 
2017 South Africa Adherence Over entire trial period 
combined behavioural activation and parenting 
programme, with sessions during pregnancy and 
following delivery, home-based counselling by lay 
counsellors 
Limited number ANC and 
postnatal support calls 
Improving early ANC attendance 
through community engagement and 






retention 6-8 weeks after birth 
community leader engagement, Community Days and 
dialogues, male and female MCH classes led by peer 
facilitators for pregnant and postpartum women 
SOC 
Friends for Life Circles for Option B 
Plus (FLCs) 2016 Uganda 
Retention and 
Adherence 2 years postpartum 
peer support groups of eight to ten women in the 
community with income generating activities to improve 
maternal adherence to clinic appointments and ART 
SOC 
Improving ART Retention and 
Adherence in Uganda: The 
WiseMama Study  
2015 Uganda adherence 6 and 9 months 
electronic pill container for ARVs, failure to open 
container within 60 minutes of dose time, triggers text 
message reminder + monthly counselling sessions 
SOC 
Kenya Enhanced Mentor Mother 
ProgrAm (EMMA) 2016 Kenya 
adherence and 
retention 72 weeks postpartum 
SOC plus study-specific enhanced care interventions from 
the clinic's Mentor Mothers. 
SOC for PMCT from clinic's 
Mentor Mothers 
Support for Perinatal Adherence and 
Depression  2017 South Africa adherence 3 months postpartum  
INSPireD: 5-8 session group intervention, to decrease 
depressive symptoms and improve adherence among 
HIV-infected pregnant and postpartum women. 
SOC counseling services, start 
intervention when first 




Postpartum Adherence Clubs for 





Adherence clubs community health workers provide 
health education, weigh participants, ask about 
symptoms, and dispense pre-packed ART. 
SOC 
Developing and Assessing a Male 
Engagement Intervention in Option 
B+ in Malawi  
2018 Malawi retention and viral suppression 1 year 
Enhanced Couple HIV Testing and Counseling, study-
specific partner referral cards to encourage male partners 
to attend ANC. Those not presenting receive three 
enhanced couple counselling sessions 
SOC 
Adaptation of the Friendship Bench 
Intervention for HIV-infected 
Perinatal Women in Lilongwe 
2019 Malawi retention 6 months 
problem solving therapy- based ART adherence support, 
individual prenatal and group postnatal counselling 
sessions. Women bring a person of their choice as social 
support to manage HIV and/or depression, assist women 
with medication collection during late 
pregnancy/postpartum, trained psychosocial counselor 
will conduct home visits 
SOC mental health in public 
facilities in Malawi 
Peer Support to Mitigate the Impact 
of Stigma in Young HIV+ Pregnant & 
Postpartum Women 
2019 South Africa Retention and viral suppression 6 months 
monthly peer support groups during pregnancy and 
postpartum, separate from routine health services, 
facilitated by WLHIV  and experience of PMTCT services 
SOC 
A Peer-Led Intervention to Improve 




1 year postpartum 
prenatal sessions and postpartum sessions with peer 
facilitator, consisting of structured educational content 
followed by unstructured conversation 
Prenatal/postpartum sessions 
with peer facilitator on 
parenting and baby care 
Mother and Infant Visit Adherence 
and Treatment Engagement Study 
(MOTIVATE!) 
2015 Kenya adherence and retention 1 year postpartum 
Home visits from community mentor mothers to assist 
with safe disclosure, safe infant feeding, safer sex , family 
planning, encourage early infant testing, promote ART 
adherence and return for HIV care visits + text messages 
SOC 
Maternal depression treatment in 




adherence and  
retention 
1 month postpartum and 
through study period 
Task-shifted depression screening and psychoeducation, 
depression diagnosis, and evidence-based problem 
solving therapy or antidepressant therapy implemented 
by trained peer mothers and midwife nurses in addition 
to usual care. 
referrals to mental health 
specialists, MOH program 
providing psychosocial 
support/ education for 
pregnancy management/ 
PMTCT adherence 
Long Term Outcomes of Therapy in 
Women Initiated on Lifelong ART 
Because of Pregnancy in DR Congo 
2017 DRC 
 
LTFU and  
Virological 
suppression 
delivery, six weeks, 12 
and 24 weeks postpartum 
CQI initiatives implemented at facility level using 
participatory data-driven approaches and on-site 
monitoring and supervisory support 
SOC + strengthening of the 
data collection system 
Evaluation of the Impact of Mobile 
Phone Messages on ART and PMTCT 
Adherence in Mozambique 
(SMSaude) 
2013 Mozambique  Retention 1 year SMS reminders to PMTCT cohort experimental group no SMS reminders 
Management and Optimization of 
Nutrition, Antenatal, Reproductive, 
Child Health & HIV Care (MONARCH) 












Appendix A: PRISMA 2009 Checklist for manuscript 




TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 - 4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
4 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
5 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
5 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
5 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
S1 Table 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
5 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
5 - 6 
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Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
6 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  6 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
6 
 




Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
6 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
6 - 7 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
7 -  9 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
9 – 27,  
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  27 - 29 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
17 - 19, 
25 – 27, 
Table 2 
and 4 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  NA 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  27 - 29 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 
16]).  
29 - 32 
DISCUSSION   
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Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
33 -39 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval 
of identified research, reporting bias).  
39 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
39- 40 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders 
for the systematic review.  
40 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 





 APPENDIX B: Submission Guidelines for Authors – PLOS One 
 
 
57 
 
 
 
58 
 
 
